<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3107233942
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Yescarta
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AXICABTAGENE CILOLEUCEL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2000000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        cells
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        As provided in the Drug Summary Bulletin
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1638037.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Kite Pharma, Inc" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Kite Pharma, Inc
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gilead Sciences Ireland UC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Yescarta is a prescription medicine used to treat two types of non-Hodgkin lymphoma:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; large B-cell lymphoma&nbsp;when your first treatment did not work or your cancer returned within a year of first treatment,&nbsp;OR&nbsp;when at least two kinds of treatment have failed to control your cancer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; follicular lymphoma when at least two kinds of treatment have failed to control your cancer.</p><p>Yescarta is different than other cancer medicines because it is made from your own white blood cells, which have been modified to recognize and attack your lymphoma cells.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Before getting Yescarta, tell your healthcare provider about all your medical problems, including if you have or have had:</strong></p><ul><li>Neurologic problems (such as seizures, stroke, or memory loss)</li><li>Lung or breathing problems</li><li>Heart problems</li><li>Liver problems</li><li>Kidney problems</li><li>A recent or active infection</li></ul><p><strong>Tell your healthcare provider about all the medications you take</strong>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p><p>&nbsp;</p><p>Yescarta may cause side effects that are life-threatening and can lead to death. Call or see your healthcare provider or get emergency help right away if you get any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (38&deg;C or higher)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills or shaking chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness or light-headedness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe nausea, vomiting, or diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast or irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe fatigue or weakness</p><p>Do not donate blood, organs, tissues or cells for transplants.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your healthcare provider before you are given Yescarta. Your doctor may need to take special care of you during your treatment with Yescarta.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>Yescarta should not be used in children and adolescents below 18 years of age.</p><p><strong>&nbsp;</strong></p><p><strong>Interactions with other medicines </strong></p><p>Tell your healthcare provider if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Before you are given Yescarta tell your doctor or nurse if you are taking any medicines that weaken your immune system such as corticosteroids, since these medicines may interfere with the effect of Yescarta.</p><p>&nbsp;</p><p>Talk to your doctor if you need to have any vaccinations.</p><p>&nbsp;</p><p><strong>Pregnancy and contraception, breast‑feeding and male fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine. This is because the effects of Yescarta in pregnant or breast-feeding women are not known, and it may harm your fetus or your breast-fed child.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant or think you may be pregnant after treatment with Yescarta, talk to your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be given a pregnancy test before treatment starts. Yescarta should only be given if the results show you are not pregnant.</p><p>Discuss pregnancy with your doctor if you have received Yescarta.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Do not drive, operate heavy machinery, or do other dangerous things for 8 weeks after you get Yescarta because the treatment can cause sleepiness, confusion, weakness, and temporary memory and coordination problems</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Yescarta<sup> </sup>will always be given to you by a healthcare provider in a qualified treatment centre.</p><p><strong>&nbsp;</strong></p><p><strong>For autologous use only. For intravenous use only.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Since Yescarta<sup> </sup>is made from your own white blood cells, your blood will be collected by a process called &ldquo;leukapheresis&rdquo;, which will concentrate your white blood cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood cells will be sent to a manufacturing center to make your Yescarta.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you get Yescarta, you will get 3 days of chemotherapy to prepare your body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When your Yescarta is ready, your healthcare provider will give it to you through a catheter placed into your vein (intravenous infusion). The infusion usually takes less than 30 minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be monitored where you received your treatment daily for at least 7 days after the infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should plan to stay close to the location where you received your treatment for at least 4 weeks after getting Yescarta. Your healthcare provider will help you with any side effects that may occur.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be hospitalized for side effects and your healthcare provider will discharge you if your side effects are under control, and it is safe for you to leave the hospital.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare provider will want to do blood tests to follow your progress. It is important that you do have your blood tested. If you miss any appointments, call your doctor or the qualified clinical facility as soon as possible to reschedule your appointment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most common side effects of Yescarta include<strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever (38&deg;C or higher)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low white blood cells (can occur with a fever)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low red blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure (dizziness or lightheadedness, headache, feeling tired, short of breath)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty speaking or slurred speech</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea</p><p>These are not all the possible side effects of Yescarta. Call your healthcare provider about any side effects that concern you.</p><p>Reporting of side effects</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The following information is intented for healthcare providers only.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the container label and infusion bag.</p><p>Store frozen in vapour phase of liquid nitrogen &le; -150&deg;C until thawed for use.</p><p>Do not refreeze.</p><p>This medicine contains genetically modified human blood cells. Local guidelines on handling of waste of human-derived material should be followed for unused medicinal product or waste material.</p><p>As this medicine will be given by qualified healthcare professionals, they are responsible for the correct disposal of the product. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is axicabtagene ciloleucel. Each patient-specific single infusion bag contains a suspension of anti-CD19 CAR T cells in approximately 68 mL for a target dose of 2 x 10<sup>6</sup> anti-CD19 CAR-positive viable T cells/kg, (range: 1 x 10<sup>6</sup> &ndash; 2 x 10<sup>6</sup> cells/kg), with a maximum of 2 x 10<sup>8</sup> anti-CD19 CAR T cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Yescarta is a clear to opaque, white to red suspension for infusion, supplied in an infusion bag individually packed in a metal cassette. A single infusion bag contains approximately 68 mL of cell suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Gilead Sciences Ireland UC</p><p>IDA Business &amp;&nbsp;Technology Park</p><p>Carrigtohill, Co. Cork</p><p>Ireland</p><p>&nbsp;</p><p><strong>Final Batch Release Site and Manufacturer </strong></p><p>Kite Pharma EU B.V.</p><p>Tufsteen 1</p><p>2132 NT Hoofddorp</p><p>The Netherlands</p><p>&nbsp;</p><p>Or</p><p>&nbsp;</p><p>Kite Pharma, Inc.</p><p>2355 Utah Avenue</p><p>El Segundo, CA 90245,</p><p>USA</p><p>&nbsp;</p><p>For any information about this medicine, please contact:</p><p>&nbsp;</p><p>Gilead Sciences Ireland Unlimited Company (KSA branch)</p><p>3074, Prince Mohammad bin Abdulaziz Rd 8022,</p><p>Al Olaya District</p><p>Postal code: 12213</p><p>Riyadh, Saudi Arabia</p><p>Email: askgileadME@gilead.com</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2022

SA-OCT23-US-NOV22
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ياسكارتا هو دواء يصرف بوصفة علاجية، يستخدم لعلاج الليمفوما اللاهودجكينية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُستخدم الدواء في علاج ليمفوما الخلايا البائية الكبيرة، إذا لم يفلح علاجك الأول، أو تكررت الإصابة خلال عام واحد من بدء علاجك الأول، أو إذا لم يفلح استخدام نوعين من العلاج على الأقل للسيطرة على نمو الخلايا السرطانية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بينما يستخدم الدواء لعلاج الليمفوما الجريبية ، إذا لم يفلح استخدام نوعين من العلاج على الأقل للسيطرة على نمو الخلايا السرطانية.</p><p dir="RTL">يختلف ياسكارتا عن أدوية علاج السرطان الأخرى لأنه مصنوع من خلايا الدم البيضاء المُعدَّلة الخاصة بك للتعرف على خلايا الورم اللمفي ومهاجمتها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>قبل تلقي ياسكارتا، أخبر مقدم الرعاية الصحية بجميع المشكلات الصحية لديك، ومنها إذا كنت تعاني من:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض عصبية (مثل نوبات الصرع أو السكتة الدماغية أو فقدان الذاكرة)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>أمراض الرئة أو التنفس</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>أمراض القلب</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>أمراض الكبد</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>أمراض الكُلى</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عدوى حديثة أو نشطة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر مقدم الرعاية الصحية الخاص بك بجميع الأدوية التي تتناولها</strong>، وتشمل الأدوية الموصوفة وتلك التي تتناولها من دون وصفة طبية، إلى جانب الفيتامينات والمكملات العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب ياسكارتا أعراضًا جانبية تهدد الحياة وقد تؤدي إلى الوفاة. اتصل بمقدم الرعاية الصحية أو توجه لزيارته أو احصل على المساعدة الطارئة على الفور إذا كنت تعاني من:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (38 درجة مئوية أو أكثر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; برودة أو قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة أو دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان أو قيء أو إسهال حاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة أو عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إجهاد أو ضعف شديد</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتبرع بالدم أو الأعضاء أو الأنسجة أو الخلايا لآخرين</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبقت عليك أي من الحالات السابقة (أو لم تكن متأكدًا من ذلك)، فتحدث إلى مقدم الرعاية الصحية قبل تلقي ياسكارتا. فقد يتعين على الطبيب تقديم الرعاية الخاصة لك خلال العلاج بواسطة ياسكارتا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يجب إعطاء ياسكارتا للأطفال والمراهقين دون سن 18 عامًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التفاعل مع الأدوية الأخرى</strong></p><p dir="RTL">أخبر مقدم الرعاية الصحية لك إذا كنت تتناول أي أدوية أخرى أو تناولتها مؤخرًا أو قد تتناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل أن تتلقى دواء ياسكارتا، أخبر الطبيب المعالج أو الممرض بما إذا كنت تتناول أي أدوية من شأنها تثبيط الجهاز المناعي مثل كورتيكوستيرويد، لأن هذه الأدوية قد تتفاعل مع تأثير ياسكارتا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ناقش الطبيب المعالج إذا كنت بحاجة لتلقي أي لقاحات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>الحمل ومنع الحمل والرضاعة‑الطبيعية وخصوبة الذكور</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعًا، أو تعتقدين أنك ربما تكونين حاملاً أو تخططين للحمل، فاطلبي الاستشارة الطبية قبل تلقي هذا الدواء. وهذا لأن تأثيرات ياسكارتا على الحوامل والمرضعات غير معلومة، وقد تلحق الضرر بالجنين أو الرضيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت حاملاً أو تعتقدين أنك ربما تصبحين حاملاً بعد العلاج باستخدام ياسكارتا، فناقشي هذه المسألة مع طبيبك على الفور.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>سوف تخضعين لاختبار حمل قبل بدء العلاج. وستتلقين ياسكارتا فقط إذا أظهرت نتيجة الاختبار عدم وجود حمل.</p><p dir="RTL">ناقشي مسألة الحمل مع طبيبك إذا كنت قد تلقيت ياسكارتا.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الماكينات</strong></p><p dir="RTL">تجنب القيادة أو تشغيل الماكينات الثقيلة أو أداء أي أنشطة أخرى محفوفة بالمخاطر لمدة 8 أسابيع بعد تلقي ياسكارتا لأن العلاج قد يسبب النعاس والارتباك والضعف ومشكلات مؤقتة في الذاكرة والتحكم في الحركة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتولى أحد مقدمي<sup> </sup>الرعاية الصحية إعطاءك دواء ياسكارتا دومًا في مركز علاج مؤهل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للاستخدام الذاتي فقط. للاستخدام الوريدي فقط.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>نظرًا لأن دواء ياسكارتا<sup> </sup>مصنوع من خلايا الدم البيضاء الخاصة بك، فسيتم الحصول على دمك من خلال عملية تُعرف باسم &quot;فصادة كرات الدم البيضاء&quot; وهي تهدف لتركيز خلايا الدم البيضاء.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>سيتم إرسال خلايا الدم لأحد مراكز التصنيع لصُنع دواء ياسكارتا الذي ستتلقاه.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قبل الحصول على ياسكارتا، ستتلقى العلاج الكيماوي لمدة 3 أيام لتحضير الجسم لاستقبال الدواء.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>بعد الانتهاء من إعداد دواء ياسكارتا الخاص بك، سيعطيك مقدم الرعاية الصحية إياه عن طريق التسريب الوريدي (قسطرة يتم إدخالها في الوريد). ويستغرق التسريب الوريدي عادةً أقل من 30 دقيقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستتم متابعة حالتك بعد تلقي العلاج يوميًا لمدة 7 أيام على الأقل بعد التسريب الوريدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تخطط للبقاء في المركز الذي تلقيت فيه العلاج لمدة 4 أسابيع على الأقل بعد الحصول على ياسكارتا. ويمكنك الاستعانة بمقدم الرعاية الصحية لمساعدتك في التغلب على أي أعراض جانبية قد تحدث لك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ربما تمكث في المستشفى لعلاج الأعراض الجانبية وسيسمح لك مقدم الرعاية الصحية بالخروج من المستشفى عند السيطرة على هذه الأعراض، وإذا كان يمكنك المغادرة بأمان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيُجري مقدم الرعاية الصحية اختبارات الدم لمتابعة تقدم الحالة لديك. وهذا أمر مهم للغاية.</p><p dir="RTL">إذا فاتك حضور أي مواعيد مقررة، فاتصل بطبيبك أو بمركز الرعاية السريرية المؤهل في أقرب وقت ممكن لتحديد موعد آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، يمكن أن يتسبب هذا الدواء في أعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي بعض الأعراض الجانبية الأكثير شيوعًا لدواء ياسكارتا<strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (38 درجة مئوية أو أكثر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كرات الدم البيضاء (قد يكون مصاحبًا للحمى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد كرات الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (ومن أعراضه الشعور بالدوخة أو الدوار، الصداع، الإرهاق، ضيق التنفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الكلام أو ثقل اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقتصر الأعراض الجانبية لدواء ياسكارتا على تلك المذكورة أعلاه. اتصل بمقدم الرعاية الصحية للاستفسار عن على أي أعراض جانبية تسبب لك القلق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الإبلاغ عن الأعراض الجانبية</p><p dir="RTL">إذا تفاقمت أي أعراض جانبية، أو إذا لاحظت أي أعراض جانبية غير مذكورة في هذه النشرة، فيُرجى إبلاغ الطبيب أو الصيدلي. وهذا يشمل أي أعراض جانبية محتملة غير مذكورة في هذه النشرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المعلومات التالية مخصصة لمقدمي الرعاية الصحية فقط.</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ الانتهاء المذكور على ملصق العبوة وكيس التسريب.</p><p dir="RTL">احفظ هذا الدواء في طور البخار للنيتروجين المسال في درجة حرارة -150 مئوية أو أقل حتى يُذاب قبل الاستخدام.</p><p dir="RTL">لا تعيد تجميده.</p><p dir="RTL">يحتوي هذا الدواء على خلايا دم بشرية مُعدلة جينيًا. ويجب اتباع الإرشادات المحلية المتعلقة بالتعامل مع نفايات المواد البشرية بالنسبة للمنتجات الدوائية غير المستخدمة أو النفايات.</p><p dir="RTL">يُعطى هذا الدواء للمريض بواسطة أخصائيي رعاية صحية مؤهلين، وبالتالي فهم مسؤولون عن التخلص من المنتج بشكل صحيح. حيث تهدف هذه التدابير إلى المحافظة على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة النشطة هي أكسيكابتاجين سيلولوسيل. يحتوي كل كيس تسريب وريدي خاص بالمريض على معلق الخلايا التائية ذات مستقبلات المستضدات الوهمية المضادة لـ CD19 بحجم 68 مل تقريبًا للجرعة المستهدفة وهي 2 &times; 10<sup>6</sup> خلية تائية صالحة مضادة لـ CD19 ذات مستقبلات المستضدات الوهمية الموجبة لكل كغم، (النطاق: 1 &times; 10<sup>6</sup> &ndash; 2 &times; 10<sup>6</sup> خلية/كغم)، بحد أقصى يبلغ 2 &times; 10<sup>8</sup> خلايا تائية ذات مستقبلات المستضدات الوهمية المضادة لـ CD19.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المظهر الخارجي لدواء ياسكارتا ومحتويات العبوة</strong></p><p dir="RTL">ياسكارتا هو دواء مُعلق شفاف مائل للكدر، أبيض مائل للحمرة يُعطى عن طريق التسريب الوريدي، ومتوفر في كيس محلول وريدي ومُغلف في علبة معدنية. يحتوي كل كيس على ما يقرب من 68 مل من المُعلق الخلوي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك رخصة التسويق</p><p dir="RTL">Gilead Sciences Ireland UC</p><p dir="RTL">IDA Business &amp;&nbsp;Technology Park</p><p dir="RTL">Carrigtohill, Co. Cork</p><p dir="RTL">Ireland</p><p dir="RTL">&nbsp;</p><p dir="RTL">موقع إطلاق الدفعة النهائية والجهة المُصنعة</p><p dir="RTL">Kite Pharma EU B.V.</p><p dir="RTL">Tufsteen 1</p><p dir="RTL">2132 NT Hoofddorp</p><p dir="RTL">The Netherlands</p><p dir="RTL">&nbsp;</p><p dir="RTL">أو</p><p dir="RTL">&nbsp;</p><p dir="RTL">Kite Pharma, Inc.</p><p dir="RTL">2355 Utah Avenue</p><p dir="RTL">El Segundo, CA 90245,</p><p dir="RTL">USA</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أي معلومات عن هذا الدواء، يُرجى الاتصال بـ:</p><p dir="RTL">&nbsp;</p><p dir="RTL">شركة Gilead Sciences Ireland Unlimited (فرع المملكة العربية السعودية)</p><p dir="RTL">3074، طريق الأمير محمد بن عبد العزيز 8022،</p><p dir="RTL">حي العليا</p><p dir="RTL">الرمز البريدي: 12213</p><p dir="RTL">الرياض، المملكة العربية السعودية</p><p dir="RTL">البريد الإلكتروني: askgileadME@gilead.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>للإبلاغ عن أي أعراض جانبية:</u><u> </u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية:</strong><strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المركز الوطني للتيقظ الدوائي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="LTR">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في  11/2022

SA-OCT23 -US-NOV22 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Yescarta 0.4 - 2 x 108 suspension for intravenous infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2.1	General description

Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy. To prepare Yescarta, a patient’s own T cells are harvested and genetically modified ex vivo by retroviral transduction to express a chimeric antigen receptor (CAR) comprising a murine anti-CD19 single chain variable fragment (scFv) linked to CD28 and CD3-zeta co-stimulatory domains. The anti-CD19 CAR T cells are expanded and infused back into the patient, where they can recognize and eliminate CD19-expressing target cells. 

Yescarta is prepared from the patient’s peripheral blood mononuclear cells, which are obtained via a standard leukapheresis procedure. The mononuclear cells are enriched for T cells and activated with anti-CD3 antibody in the presence of IL-2, then transduced with the replication incompetent retroviral vector containing the anti-CD19 CAR transgene. The transduced T cells are expanded in cell culture, washed, formulated into a suspension, and cryopreserved. The product must pass a sterility test before release for shipping as a frozen suspension in a patient-specific infusion bag. The product is thawed prior to infusion (see section 4.2).

2.2	Qualitative and quantitative composition

A single dose of Yescarta contains 2 × 106 CAR-positive viable T cells per kg of body weight (or maximum of 2 × 108 CAR-positive viable T cells for patients 100 kg and above) in approximately 68 mL suspension in an infusion bag.

Excipients with known effect

Each bag of Yescarta contains 300 mg sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cell suspension for intravenous infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Yescarta is indicated for the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.</p><p><u>&nbsp;</u></p><p><u>Limitations of Use</u>: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.</p><p><strong>&nbsp;</strong></p><p>Follicular Lymphoma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yescarta is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Yescarta must be administered in a qualified treatment centre by a physician with experience in the treatment of haematological malignancies and trained for administration and management of patients treated with Yescarta. At least 1 dose of tocilizumab for use in the event of cytokine release syndrome (CRS) and emergency equipment must be available prior to infusion.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Each single infusion bag of Yescarta contains a suspension of CAR-positive T cells in approximately 68 mL. The target dose is 2 &times; 10<sup>6</sup> CAR-positive viable T cells per kg body weight, with a maximum of 2 &times; 10<sup>8</sup> CAR-positive viable T cells.</p><p>&nbsp;</p><p>Confirm availability of Yescarta prior to starting the lymphodepleting regimen.</p><p><em>&nbsp;</em></p><p><em>Pre-treatment</em></p><ul><li>Administer a lymphodepleting chemotherapy regimen of cyclophosphamide 500&nbsp;mg/m<sup>2</sup> intravenously and fludarabine 30&nbsp;mg/m<sup>2</sup> intravenously on the fifth, fourth, and third day before infusion of Yescarta.</li></ul><p><em>&nbsp;</em></p><p><em>Pre-medication</em></p><ul><li>Administer acetaminophen/paracetamol 650&nbsp;mg PO and diphenhydramine 12.5&nbsp;mg intravenously or PO approximately 1 hour before Yescarta infusion.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider the use of prophylactic corticosteroid in patients after weighing the potential benefits and risks (see Tables 1 and 2).</p><p><em>&nbsp;</em></p><p><em>Monitoring</em></p><ul><li>Administer Yescarta at a certified healthcare facility.</li><li>Monitor patients at least daily for 7 days at the certified healthcare facility following infusion for signs and symptoms of CRS and neurologic toxicities.</li><li>Instruct patients to remain within proximity of the certified healthcare facility for at least 4 weeks following infusion.</li></ul><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>Patients with human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.</p><p>There is limited clinical experience in patients with active HIV, HBV or HCV infection.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Yescarta in children and adolescents below 18 years of age have not yet been established.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No clinically important differences in safety or effectiveness were observed between patients aged 65 years and older and younger patients.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>Yescarta is to be administered via intravenous infusion</p><p>&nbsp;</p><p><em>Precautions to be taken before handling or administering Yescarta</em></p><p>Yescarta contains human blood cells that are genetically modified with replication incompetent retroviral vector. Follow universal precautions and local biosafety guidelines for handling and disposal to avoid potential transmission of infectious diseases.</p><p><u>&nbsp;</u></p><p>Preparation of Yescarta for Infusion</p><p>Coordinate the timing of Yescarta thaw and infusion. Confirm the infusion time in advance, and adjust the start time of Yescarta thaw such that it will be available for infusion when the patient is ready.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirm patient identity: Prior to Yescarta preparation, match the patient&rsquo;s identity with the patient identifiers on the Yescarta cassette.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not remove the Yescarta product bag from the cassette if the information on the patient-specific label does not match the intended patient.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once patient identification is confirmed, remove the Yescarta product bag from the cassette and check that the patient information on the cassette label matches the bag label.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inspect the product bag for any breaches of container integrity such as breaks or cracks before thawing. If the bag is compromised, follow the local guidelines for the handling of waste of human-derived material.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the infusion bag inside a second sterile bag per local guidelines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thaw Yescarta at approximately 37&deg;C using either a water bath or dry thaw method until there is no visible ice in the infusion bag. Gently mix the contents of the bag to disperse clumps of cellular material. If visible cell clumps remain continue to gently mix the contents of the bag. Small clumps of cellular material should disperse with gentle manual mixing. Do not wash, spin down, and/or re-suspend Yescarta in new medium prior to infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once thawed, Yescarta may be stored at room temperature (20&deg;C to 25&deg;C) for up to 3 hours.</p><p>&nbsp;</p><p>Administration</p><p>Yescarta is for autologous use only. The patient&rsquo;s identity must match the patient identifiers on the Yescarta cassette and infusion bag. Do not infuse Yescarta if the information on the patient-specific label does not match the intended patient.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ensure that tocilizumab and emergency equipment are available prior to infusion and during the recovery period.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do NOT use a leukodepleting filter.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Central venous access is recommended for the infusion of Yescarta.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confirm the patient&rsquo;s identity matches the patient identifiers on the Yescarta product bag.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prime the tubing with normal saline prior to infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infuse the entire contents of the Yescarta bag within 30 minutes by either gravity or a peristaltic pump. Yescarta is stable at room temperature for up to 3 hours after thaw.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently agitate the product bag during Yescarta infusion to prevent cell clumping.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the entire content of the product bag is infused, rinse the tubing with normal saline at the same infusion rate to ensure all product is delivered.</p><p>&nbsp;</p><p><strong>For instructions on the handling, accidental exposure to and disposal of the medical product, see section&nbsp;6.6.</strong></p><p>&nbsp;</p><p><u>Management of Severe Adverse Reactions </u></p><p>&nbsp;</p><p><em>Cytokine Release Syndrome</em></p><p>Identify CRS based on clinical presentation (see section 4.4). Evaluate for and treat other causes of fever, hypoxia, and hypotension. If CRS is suspected, manage according to the recommendations in Table 1. Patients who experience Grade 2 or higher CRS (e.g., hypotension not responsive to fluids, or hypoxia requiring supplemental oxygenation) should be monitored with continuous cardiac telemetry and pulse oximetry. For patients experiencing severe CRS, consider performing an echocardiogram to assess cardiac function. For severe or life-threatening CRS, consider intensive-care supportive therapy.</p><p>&nbsp;</p><p>Table <!--[if supportFields]><span style='mso-bookmark:
_Ref490157471'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref490157471'><span lang=EN-GB><span
style='mso-spacerun:yes'> </span>SEQ Table \* ARABIC <span style='mso-element:
field-separator'></span></span></span><![endif]-->1<!--[if supportFields]><span
style='mso-bookmark:_Ref490157471'></span><span style='mso-element:field-end'></span><![endif]-->.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CRS Grading and Management Guidance</p><table border="1" cellspacing="0" cellpadding="0" summary="Table 1. CRS Grading and Management Guidance.

CRS Grade Refer to footnote a. Grade 1: Symptoms require symptomatic treatment only (e.g., fever, nausea, fatigue, headache, myalgia, malaise). Tocilizumab: If not improving after 24 hours,  manage as Grade 2. Corticosteroids: If not improving after 3 days,  administer one dose of dexamethasone 10 mg intravenously.

CRS Grade Refer to footnote a. Grade 2. Symptoms require and respond to moderate intervention. Oxygen requirement less than 40% FiO2 or hypotension responsive to fluids or low-dose of one vasopressor or Grade 2 organ toxicity. Refer to footnote b. Tocilizumab: Administer tocilizumab. Refer to footnote c.  8 mg/kg intravenously over 1 hour (not to exceed 800 mg). If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed. Limit to a maximum of 3 doses in a 24-hour period; maximum total of 4 doses. If improving, discontinue tocilizumab. Corticosteroids: Administer dexamethasone 10 mg intravenously once daily. 
If improving, manage as Grade 1 above and continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate. 
If not improving, manage as appropriate grade below.

CRS Grade Refer to footnote a. Grade 3. Symptoms require and respond to aggressive intervention. Oxygen requirement greater than or equal to 40% FiO2 or hypotension requiring high-dose or multiple vasopressors or Grade 3 organ toxicity or Grade 4 transaminitis. Tocilizumab: Per Grade 2. If improving, manage as appropriate grade above. Corticosteroids: Dexamethasone 10 mg intravenously three times a day. 
If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate.
If not improving, manage as Grade 4.


CRS Grade Refer to footnote a. Grade 4. Life-threatening symptoms. Requirements for ventilator support or continuous veno-venous hemodialysis (CVVHD), or Grade 4 organ toxicity (excluding transaminitis). Tocilizumab: Per Grade 2. If improving, manage as appropriate grade above. Corticosteroids: Administer methylprednisolone 1000 mg intravenously once per day for 3 days. 
If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.
If not improving, consider methylprednisolone 1000 mg 2-3 times a day or alternate therapy. Refer to footnote d.

Footnotes 
a. Lee et al. 2014. 
b. Refer to Table 2 for management of neurologic toxicity.  
c. Refer to tocilizumab Prescribing Information for details.
d. Alternate therapy includes (but is not limited to): anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG and ATG.
" align="left" style="width:612px"><thead><tr><td style="vertical-align:top"><p>CRS Grade<sup> a</sup></p></td><td style="vertical-align:top"><p>Tocilizumab</p></td><td style="vertical-align:top"><p>Corticosteroids</p></td></tr><tr><td style="vertical-align:top"><p>Grade 1</p><p>Symptoms require symptomatic treatment only (e.g., fever, nausea, fatigue, headache, myalgia, malaise).</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>If symptoms (e.g., fever) not improving after 24 hours, consider managing as Grade 2.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>If not improving after 3 days, administer one dose of dexamethasone 10 mg intravenously.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2</p><p>Symptoms require and respond to moderate intervention.</p><p>Oxygen requirement less than 40% FiO<sub>2</sub> or hypotension responsive to fluids or low-dose of one vasopressor or</p><p>Grade 2 organ toxicity.<sup>b</sup></p></td><td style="vertical-align:top"><p>Administer tocilizumab<sup>c</sup> 8 mg/kg intravenously over 1 hour (not to exceed 800 mg).</p><p>If no clinical improvement in the signs and symptoms of CRS after the first dose, repeat tocilizumab every 8 hours as needed.</p><p>Limit to a maximum of 3 doses in a 24-hour period; maximum total of 4 doses.</p><p>&nbsp;</p><p>If improving, discontinue tocilizumab.</p></td><td style="vertical-align:top"><p>Administer dexamethasone 10 mg intravenously once daily.</p><p>If improving, manage as Grade 1 above and continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate.</p><p>If not improving, manage as appropriate grade below.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p><p>Symptoms require and respond to aggressive intervention.</p><p>Oxygen requirement greater than or equal to 40% FiO<sub>2</sub> or hypotension requiring high-dose or multiple vasopressors or</p><p>Grade 3 organ toxicity or Grade 4 transaminitis.</p></td><td style="vertical-align:top"><p>Per Grade 2.</p><p>If improving, manage as appropriate grade above.</p></td><td style="vertical-align:top"><p>Dexamethasone 10 mg intravenously three times a day.</p><p>If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate.</p><p>If not improving, manage as Grade 4.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p><p>Life-threatening symptoms.</p><p>Requirements for ventilator support, continuous veno-venous hemodialysis (CVVHD) or</p><p>Grade 4 organ toxicity (excluding transaminitis).</p></td><td style="vertical-align:top"><p>Per Grade 2.</p><p>If improving, manage as appropriate grade above.</p></td><td style="vertical-align:top"><p>Administer methylprednisolone 1000 mg intravenously once per day for 3 days.</p><p>If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.</p><p>If not improving, consider methylprednisolone 1000 mg 2-3 times a day or alternate therapy.<sup>d</sup></p></td></tr></thead></table><p>&nbsp;</p><p>&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p><em>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Lee et al. 2014.</p><p><em>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Refer to Table 2 for management of neurologic toxicity.&nbsp;</p><p><em>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Refer to tocilizumab Prescribing Information for details.</p><p><em>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>Alternate therapy includes (but is not limited to): anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG and ATG.</p><p><strong><em>&nbsp;</em></strong></p><p><em>Neurologic Toxicity</em></p><p>Monitor patients for signs and symptoms of neurologic toxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) (Table 2). Rule out other causes of neurologic symptoms. Patients who experience Grade 2 or higher neurologic toxicities/ICANS should be monitored with continuous cardiac telemetry and pulse oximetry. Provide intensive-care supportive therapy for severe or life-threatening neurologic toxicities. Consider levetiracetam for seizure prophylaxis for any grade of neurologic toxicities.</p><p style="text-indent:50px">&nbsp;</p><p><strong>Table </strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-GB style='color:#2B579A;background:#E6E6E6'><span
style='mso-element:field-begin'></span></span><span lang=EN-GB><span
style='mso-spacerun:yes'> </span>SEQ Table \* ARABIC <span style='color:#2B579A;
background:#E6E6E6'><span style='mso-element:field-separator'></span></span></span></b><![endif]--><strong>2</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='color:#2B579A;
background:#E6E6E6'><span style='mso-element:field-end'></span></span></b><![endif]--><strong>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neurologic Toxicity/ICANS Grading and Management Guidance</strong></p><table border="1" cellspacing="0" cellpadding="0" summary="Table 2. Neurologic Toxicity Grading and Management Guidance.

Grading Assessment. Refere to footnote a. Grade 1. Concurrent CRS: Administer tocilizumab per Table 1 for management of Grade 1 CRS.
In addition, administer one dose of dexamethasone 10 mg intravenously.
If not improving after 2 days, repeat dexamethasone 10 mg intravenously.
Consider levetiracetam for seizure prophylaxis. Grade 1. No Concurrent CRS: Administer one dose of dexamethasone 10 mg intravenously. If not improving after 2 days, repeat dexamethasone 10 mg intravenously. Consider levetiracetam for seizure prophylaxis. Grade 2. Concurrent CRS: Administer tocilizumab per Table 1 for management of Grade 2 CRS.
In addition, administer dexamethasone 10 mg intravenously four times a day.
If improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate.
If not improving, manage as appropriate grade below. Consider levetiracetam for seizure prophylaxis. 

No Concurrent CRS: Administer dexamethasone 10 mg intravenously four times a day.
If improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate.                                                                          
If not improving, manage as appropriate grade below. Consider levetiracetam for seizure prophylaxis. 

Grading Assessment 3. Grade 3. Concurrent CRS: Administer tocilizumab per Table 1 for management of Grade 2 CRS. 
In addition, administer methylprednisolone 1000 mg intravenously once daily. 
If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.
If not improving, manage as Grade 4.
Consider levetiracetam for seizure prophylaxis.
No Concurrent CRS: Administer methylprednisolone 1000 mg intravenously once daily. 
If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.
If not improving, manage as Grade 4.

Grading Assessment. Grade 4. Concurrent CRS: Administer tocilizumab per Table 1 for management of Grade 2 CRS. 
In addition, administer methylprednisolone 1000 mg intravenously twice per day.
If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.
If not improving, consider 1000 mg of methylprednisolone intravenously 3 times a day or alternate therapy. Refer to footnote b.
Consider levetiracetam for seizure prophylaxis. No Concurrent CRS: Administer methylprednisolone 1000 mg intravenously twice per day. If not improving, consider 1000 mg of methylprednisolone intravenously 3 times a day or alternate therapy. Refer to footnote b.  Consider levetiracetam for seizure prophylaxis.
Footnotes:
a. Severity based on Common Terminology Criteria for Adverse Events. 
b. Alternate therapy includes (but is not limited to): anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG and ATG.
" style="width:606px"><thead><tr><td><p><strong>Grading Assessment <sup>a</sup></strong></p></td><td><p><strong>Concurrent CRS</strong></p></td><td><p><strong>No Concurrent CRS</strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade 1</strong></p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table 1 for management of Grade 1 CRS.</p><p>In addition, administer one dose of dexamethasone 10 mg intravenously.</p><p>If not improving after 2 days, repeat dexamethasone 10 mg intravenously.</p></td><td style="vertical-align:top"><p>Administer one dose of dexamethasone 10 mg intravenously.</p><p>If not improving after 2 days, repeat dexamethasone 10 mg intravenously.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider levetiracetam for seizure prophylaxis.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade 2</strong></p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table 1 for management of Grade 2 CRS.</p><p>In addition, administer dexamethasone 10 mg intravenously four times a day.</p><p>If improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate.</p><p>If not improving, manage as appropriate grade below.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Administer dexamethasone 10 mg intravenously four times a day.</p><p>If improving, continue corticosteroids until the severity is Grade 1 or less, then quickly taper as clinically appropriate.</p><p>If not improving, manage as appropriate grade below.</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider levetiracetam for seizure prophylaxis.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table 1 for management of Grade 2 CRS.</p><p>In addition, administer methylprednisolone 1000 mg intravenously once daily.</p><p>If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.</p><p>If not improving, manage as Grade 4.</p></td><td style="vertical-align:top"><p>Administer methylprednisolone 1000 mg intravenously once daily.</p><p>If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.</p><p>If not improving, manage as Grade 4.</p><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider levetiracetam for seizure prophylaxis.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Grade 4</strong></p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table 1 for management of Grade 2 CRS.</p><p>In addition, administer methylprednisolone 1000 mg intravenously twice per day.</p><p>If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.</p><p>If not improving, consider 1000 mg of methylprednisolone intravenously 3 times a day or alternate therapy.<sup>b</sup></p></td><td style="vertical-align:top"><p>Administer methylprednisolone 1000 mg intravenously twice per day.</p><p>If improving, manage as appropriate grade above and continue corticosteroids until the severity is Grade 1 or less, then taper as clinically appropriate.</p><p>If not improving, consider 1000 mg of methylprednisolone intravenously 3 times a day or alternate therapy.<sup>b</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider levetiracetam for seizure prophylaxis.</p></td></tr></tbody></table><p style="text-indent:50px">&nbsp;</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severity based on Common Terminology Criteria for Adverse Events.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternate therapy includes (but is not limited to): anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG and ATG.</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p><p style="text-indent:50px">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cytokine Release Syndrome </u></p><p>&nbsp;</p><p>CRS, including fatal or life-threatening reactions, occurred following treatment with Yescarta. CRS occurred in 90% (379/422) of patients with non-Hodgkin lymphoma (NHL) receiving Yescarta, including &ge; Grade 3 (Lee grading system<sup>1</sup>) CRS in 9%. CRS occurred in 93% (256/276) of patients with large B-cell lymphoma (LBCL), including &ge; Grade 3 CRS in 9% (see section 4.8). Among patients with LBCL who died after receiving Yescarta, four had ongoing CRS events at the time of death. For patients with LBCL in ZUMA-1, the median time to onset of CRS was 2 days following infusion (range: 1 to 12 days) and the median duration of CRS was 7 days (range: 2 to 58 days). For patients with LBCL in ZUMA-7, the median time to onset of CRS was 3 days following infusion (range: 1 to 10 days) and the median duration was 7 days (range: 2 to 43 days).</p><p>&nbsp;</p><p>CRS occurred in 84% (123/146) of patients with indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5, including &ge; Grade 3 CRS in 8% (see section 4.8). Among patients with iNHL who died after receiving Yescarta, one patient had an ongoing CRS event at the time of death. The median time to onset of CRS was 4 days (range: 1 to 20 days) and the median duration was 6 days (range: 1 to 27 days) for patients with iNHL.</p><p>&nbsp;</p><p>Key manifestations of CRS (&ge; 10%) in all patients combined included fever (85%), hypotension (40%), tachycardia (32%), chills (22%), hypoxia (20%), headache (15%), and fatigue (12%). Serious events that may be associated with CRS include, cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), renal insufficiency, cardiac failure, respiratory failure, cardiac arrest, capillary leak syndrome, multi-organ failure, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) (see section 4.8)<em>.</em></p><p>&nbsp;</p><p>The impact of tocilizumab and/or corticosteroids on the incidence and severity of CRS was assessed in two subsequent cohorts of LBCL patients in ZUMA-1. Among patients who received tocilizumab and/or corticosteroids for ongoing Grade 1 events (see Table 1) (see section 4.8), CRS occurred in 93% (38/41), including 2% (1/41) with Grade 3 CRS; no patients experienced a Grade 4 or 5 event. The median time to onset of CRS was 2 days (range: 1 to 8 days) and the median duration of CRS was 7 days (range: 2 to 16 days).</p><p>&nbsp;</p><p>Prophylactic treatment with corticosteroids was administered to a cohort of 39 patients for 3 days beginning on the day of infusion of Yescarta (see section 4.8). Thirty-one of the 39 patients (79%) developed CRS at which point the patients were managed with tocilizumab and/or therapeutic doses of corticosteroids with no patients developing Grade 3 or higher CRS. The median time to onset of CRS was 5 days (range: 1 to 15 days) and the median duration of CRS was 4 days (range: 1 to 10 days). Although there is no known mechanistic explanation, consider the risk and benefits of prophylactic corticosteroids in the context of pre-existing comorbidities for the individual patient and the potential for the risk of Grade 4 and prolonged neurologic toxicities (see section 4.4).</p><p>&nbsp;</p><p>Ensure that 2 doses of tocilizumab are available prior to infusion of Yescarta. Monitor patients at least daily for 7 days at the certified healthcare facility following infusion for signs and symptoms of CRS. Monitor patients for signs or symptoms of CRS for 4 weeks after infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated<em> </em>(see section 4.2).<em> </em></p><p><strong>&nbsp;</strong></p><p><u>Neurologic Toxicities</u></p><p>Neurologic toxicities (including ICANS) that were fatal or life-threatening occurred following treatment with Yescarta. Neurologic toxicities occurred in 78% (330/422) of patients with NHL receiving Yescarta, including &ge; Grade 3 cases in 25%.</p><p>Neurologic toxicities occurred in 87% (94/108) of patients with LBCL in ZUMA-1, including &ge; Grade 3 cases in 31% and in 74% (124/168) of patients in ZUMA-7 including &ge; Grade 3 cases in 25%. The median time to onset was 4 days (range: 1 to 43 days) and the median duration was 17 days in patients with LBCL in ZUMA-1. The median time to onset for neurologic toxicity was 5 days (range:1 to 133 days) and median duration was 15 days in patients with LBCL in ZUMA-7. Neurologic toxicities occurred in 77% (112/146) of patients with iNHL, including &ge; Grade 3 in 21%. The median time to onset was 6 days (range: 1 to 79 days) and the median duration was 16 days. Ninety-eight percent of all neurologic toxicities in patients with LBCL and 99% of all neurologic toxicities in patients with iNHL occurred within the first 8 weeks of Yescarta infusion. Neurologic toxicities occurred within the first 7 days of Yescarta infusion in 87% of affected patients with LBCL and 74% of affected patients with iNHL.</p><p>The most common neurologic toxicities (&ge; 10%) in all patients combined included encephalopathy (50%), headache (43%), tremor (29%), dizziness (21%), aphasia (17%), delirium (15%), and insomnia (10%). Prolonged encephalopathy lasting up to 173 days was noted. Serious events including aphasia, leukoencephalopathy, dysarthria, lethargy, and seizures occurred with Yescarta. Fatal and serious cases of cerebral edema and encephalopathy, including late-onset encephalopathy, have occurred in patients treated with Yescarta.</p><p>&nbsp;</p><p>The impact of tocilizumab and/or corticosteroids on the incidence and severity of neurologic toxicities was assessed in two subsequent cohorts of LBCL patients in ZUMA-1. Among patients who received corticosteroids at the onset of Grade 1 toxicities (see Table 2), neurologic toxicities occurred in 78% (32/41) and 20% (8/41) had Grade 3 neurologic toxicities; no patients experienced a Grade 4 or 5 event. The median time to onset of neurologic toxicities was 6 days (range: 1 to 93 days) with a median duration of 8 days (range: 1 to 144 days). Prophylactic treatment with corticosteroids was administered to a cohort of 39 patients for 3 days beginning on the day of infusion of Yescarta (see section 4.8). Of these 39 patients, 85% (33/39) developed neurologic toxicities; 8% (3/39) developed Grade 3 and 5% (2/39) developed Grade 4 neurologic toxicities. The median time to onset of neurological toxicities was 6 days (range: 1 to 274 days) with a median duration of 12 days (range: 1 to 107 days). Prophylactic corticosteroids for management of CRS and neurologic toxicities may result in higher grade of neurologic toxicities or prolongation of neurologic toxicities, delay the onset and decrease the duration of CRS (see section 4.4).</p><p>&nbsp;</p><p>Monitor patients at least daily for 7 days at the certified healthcare facility following infusion for signs and symptoms of neurologic toxicities. Monitor patients for signs or symptoms of neurologic toxicities for 4 weeks after infusion and treat promptly (see section 4.2).</p><p>&nbsp;</p><p><u>Restricted access program requirements</u></p><p>&nbsp;</p><p>Because of the risk of CRS and neurologic toxicities, Yescarta is available only through a restricted program. The required components of the Yescarta<sup> </sup>program are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Healthcare facilities that dispense and administer Yescarta must be certified and comply with the restricted access program requirements. Certified healthcare facilities must have on-site, immediate access to tocilizumab, and ensure that a minimum of 2 doses of tocilizumab are available for each patient for infusion within 2 hours after Yescarta<sup> </sup>infusion, if needed for treatment of CRS.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certified healthcare facilities must ensure that healthcare providers who prescribe, dispense, or administer Yescarta<sup> </sup>are trained about the management of CRS and neurologic toxicities.</p><p>&nbsp;</p><p><u>Hypersensitivity Reactions</u></p><p>&nbsp;</p><p>Allergic reactions may occur with the infusion of Yescarta. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) or residual gentamicin in Yescarta.</p><p>&nbsp;</p><p><u>Serious Infections </u></p><p>&nbsp;</p><p>Severe or life-threatening infections occurred in patients after Yescarta infusion. Infections (all grades) occurred in 45% of patients with NHL. Grade 3 or higher infections occurred in 17% of patients, including Grade 3 or higher infections with an unspecified pathogen in 12%, bacterial infections in 5%, viral infections in 3%, and fungal infections in 1%. Yescarta should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after Yescarta infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines.</p><p>&nbsp;</p><p>Febrile neutropenia was observed in 36% of patients with NHL after Yescarta infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.</p><p>&nbsp;</p><p>In immunosuppressed patients, including those who have received Yescarta, life-threatening and fatal opportunistic infections including disseminated fungal infections (e.g., candida sepsis and aspergillus infections) and viral reactivation (e.g., human herpes virus-6 [HHV-6] encephalitis and JC virus progressive multifocal leukoencephalopathy [PML]) have been reported. The possibility of HHV-6 encephalitis and PML should be considered in immunosuppressed patients with neurologic events and appropriate diagnostic evaluations should be performed.</p><p>&nbsp;</p><p><em>Hepatitis B Virus Reactivation </em></p><p>Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred in patients treated with drugs directed against B cells, including Yescarta. Perform screening for HBV, HCV, and HIV and management in accordance with clinical guidelines before collection of cells for manufacturing.</p><p>&nbsp;</p><p><u>Prolonged Cytopenias </u></p><p>&nbsp;</p><p>Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and Yescarta infusion. Grade 3 or higher cytopenias not resolved by Day 30 following Yescarta infusion occurred in 39% of all patients with NHL and included neutropenia (33%), thrombocytopenia (13%), and anemia (8%). Monitor blood counts after Yescarta infusion.</p><p>&nbsp;</p><p><u>Hypogammaglobulinemia</u></p><p>&nbsp;</p><p>B-cell aplasia and hypogammaglobulinemia can occur in patients receiving treatment with Yescarta. Hypogammaglobulinemia was reported as an adverse reaction in 14% of all patients with NHL. Monitor immunoglobulin levels after treatment with Yescarta and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement.</p><p>&nbsp;</p><p>The safety of immunization with live viral vaccines during or following Yescarta treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during Yescarta treatment, and until immune recovery following treatment with Yescarta.</p><p>&nbsp;</p><p><u>Secondary Malignancies</u></p><p>&nbsp;</p><p>Patients treated with Yescarta may develop secondary malignancies. Monitor life-long for secondary malignancies. In the event that a secondary malignancy occurs, contact the company to obtain instructions on patient samples to collect for testing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with Yescarta.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p>There are no available data with Yescarta use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with Yescarta to assess whether it can cause fetal harm when administered to a pregnant woman. It is not known if Yescarta has the potential to be transferred to the fetus. Based on the mechanism of action, if the transduced cells cross the placenta, they may cause fetal toxicity, including B-cell lymphocytopenia. Therefore, Yescarta is not recommended for women who are pregnant, and pregnancy after Yescarta infusion should be discussed with the treating physician.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>There is no information regarding the presence of Yescarta in human milk, the effect on the breastfed infant, and the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for Yescarta and any potential adverse effects on the breastfed infant from Yescarta or from the underlying maternal condition.</p><p><u>&nbsp;</u></p><p><u>Pregnancy Testing</u></p><p>&nbsp;</p><p>Pregnancy status of females with reproductive potential should be verified. Sexually active females of reproductive potential should have a pregnancy test prior to starting treatment with Yescarta.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>&nbsp;</p><p>See the prescribing information for fludarabine and cyclophosphamide for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy.</p><p>There are insufficient exposure data to provide a recommendation concerning duration of contraception following treatment with Yescarta.</p><p><u>&nbsp;</u></p><p><u>Infertility</u></p><p>&nbsp;</p><p>There are no data on the effect of Yescarta on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to the potential for neurologic events, including altered mental status or seizures, patients receiving Yescarta are at risk for altered or decreased consciousness or coordination in the 8 weeks following Yescarta infusion. Advise patients to refrain from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery, during this initial period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions are described elsewhere in the labelling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytokine Release Syndrome (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neurologic Toxicities (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity Reactions (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious Infections (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged Cytopenias (see section 4.4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinemia (see section 4.4)</p><p><strong><u>&nbsp;</u></strong></p><p><u>Clinical Trials Experience </u></p><p>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>&nbsp;</p><p>The data described in the Special warnings and precautions for use reflect exposure to a single dose of Yescarta in one randomized, open-label study with 168 patients with relapsed or refractory LBCL (ZUMA-7) and two open-label, single-arm studies with 108 patients with relapsed or refractory LBCL (ZUMA-1 study) and 146 patients with relapsed or refractory iNHL (including 124 with FL; ZUMA-5 study).</p><p><u>&nbsp;</u></p><p><u>Relapsed or Refractory Large B-cell Lymphoma</u></p><p><em>&nbsp;</em></p><p><em>ZUMA-7</em></p><p>The safety of Yescarta was evaluated in ZUMA-7, a randomized, open-label, multicenter study in which patients with primary refractory LBCL or first relapse of LBCL received Yescarta (N = 168) or standard therapy (N = 168) (see section 5.1). Patients had not yet received treatment for relapsed or refractory lymphoma and were potential candidates for autologous hematopoietic stem cell transplantation (HSCT). The trial excluded patients who were not deemed candidates for transplant or who had a history of central nervous system (CNS) disorders (such as seizures or cerebrovascular ischemia), serious or uncontrolled infection, or autoimmune disease requiring systemic immunosuppression. The study required ANC &ge; 1000/mm3, platelet count &ge; 75,000/mm3, creatinine clearance &ge; 60 ml/min, AST/ALT &le; 2.5 x ULN, and total bilirubin &le; 1.5mg/dL. &nbsp;</p><p>The median age of the Yescarta-treated safety population was 59 years (range: 21 to 80 years); 62% were male. The baseline Eastern Cooperative Oncology Group (ECOG) performance status was 0 in 54% of patients and 1 in 46%.</p><p>The most common non-laboratory adverse reactions to Yescarta (incidence &ge; 20%) included fever, CRS, fatigue, hypotension, encephalopathy, tachycardia, diarrhea, headache, musculoskeletal pain, nausea, febrile neutropenia, chills, cough, infection with unspecified pathogen, dizziness, tremor, decreased appetite, edema, hypoxia, abdominal pain, aphasia, constipation, and vomiting. Serious adverse reactions occurred in 50% of patients. The most common serious adverse reactions (&gt; 5%) included CRS, fever, encephalopathy, hypotension, infection with unspecified pathogen, and pneumonia.&nbsp; Fatal adverse reactions occurred in 2% of patients.</p><p>The most common (&ge; 10%) Grade 3 or higher non-laboratory adverse reactions included febrile neutropenia, encephalopathy, and hypotension.</p><p>Sixty-seven percent (112/168) of patients received tocilizumab after infusion of Yescarta.</p><p>Table 3 summarizes selected non-laboratory adverse reactions in patients treated with Yescarta, and Table 4 summarizes selected new or worsening Grade 3 or 4 laboratory abnormalities.</p><p><strong>Table 3.</strong>&nbsp;&nbsp;&nbsp; <strong>Adverse Reactions in &ge;10% of Patients Treated with Yescarta in ZUMA-7</strong></p><table border="0" cellspacing="0" cellpadding="0" summary="Table 3. Summary of Adverse Reactions Observed in at Least 10% of Patients Treated with Yescarta in ZUMA-7 (N=168)
Febrile neutropenia. Any Grade: 34%. Grade 3 or Higher: 31%.
Cardiac Disorders  
Tachycardias (Refer to footnote a.). Tachycardias in Any Grade is 43%. Tachycardias in Grade 3 or Higher: 2%.
Arrhythmias Refer to footnote b. Any Grade: 23%. Grade 3 or Higher: 7%.

Gastrointestinal Disorders  
Diarrhea. Any Grade: 38%. Grade 3 or Higher: 4%.      
Nausea. Any Grade: 34%. Grade 3 or Higher: 0%.         
Vomiting. Any Grade: 26%. Grade 3 or Higher: 1%. 
Constipation. Any Grade: 23%. Grade 3 or Higher: 0%.
Abdominal pain Refer to footnote c. Any Grade: 14%. Grade 3 or Higher: 1%.
Dry mouth. Any Grade: 11%. Grade 3 or Higher: 0%.

General Disorders and Administration Site Conditions  
Fever. Refer to footnote d. Any Grade: 86%. Grade 3 or Higher: 16%.
Fatigue Refer to footnote e. Any Grade: 46%. Grade 3 or Higher: 3%.
Chills. Any Grade: 40%. Grade 3 or Higher: 0%.
Edema Refer to footnote f. Any Grade: 19%. Grade 3 or Higher: 1%.

Immune System Disorders  
Cytokine release syndrome. Any Grade: 94%. Grade 3 or Higher: 13%.
Hypogammaglobulinemia Refer to footnote g. Any Grade: 15%. Grade 3 or Higher: 0%.

Infections and Infestations  
Infection with pathogen unspecified. Any Grade: 26%. Grade 3 or Higher: 16%. 
Viral infections. Any Grade: 16%. Grade 3 or Higher: 4%.
Bacterial infections. Any Grade: 13%. Grade 3 or Higher: 9%.
                                                                                                                              
Investigations                                                                                               
Decreased appetite. Any Grade 44%. Grade 3 or Higher: 2%.                                                                                                                Weight decreased. Any Grade 16%. Grade 3 or Higher: 0%.                                                                                                                Dehydration. Any Grade 11%. Grade 3 or Higher: 3%.          
                                                                                                             
Musculoskeletal and Connective Tissue Disorders  
Motor dysfunction. Refer to footnote h. Any Grade: 19%. Grade 3 or Higher: 1%.
Pain in extremity. Refer to footnote i. Any Grade: 17%. Grade 3 or Higher: 2%.
Back pain. Any Grade: 15%. Grade 3 or Higher: 1%.
Muscle pain. Any Grade: 14%. Grade 3 or Higher: 1%.
Arthralgia. Any Grade: 10%. Grade 3 or Higher: 0%.                   
                                                                                                                        
Nervous System Disorders  
Encephalopathy Refer to footnote j. Any Grade: 57%. Grade 3 or Higher: 29%. 
Headache Refer to footnote k. Any Grade: 45%. Grade 3 or Higher: 1%.
Tremor. Any Grade: 31%. Grade 3 or Higher: 2%.         
Dizziness Refer to footnote l.  Any Grade: 21%. Grade 3 or Higher: 1%.                                                                                                        Aphasia Refer to footnote m. Any Grade: 18%. Grade 3 or Higher: 6%. 

Psychiatric Disorders  
Delirium Refer to footnote m. Any Grade:17%. Grade 3 or Higher: 6%.                                                                                                                       
Respiratory, Thoracic and Mediastinal Disorders  
Hypoxia. Refer to footnote o. Any Grade: 32%. Grade 3 or Higher: 11%. 
Cough Refer to footnote p. Any Grade: 30%. Grade 3 or Higher: 0%.
Dyspnea Refer to footnote q. Any Grade: 19%. Grade 3 or Higher: 3%. 
Pleural effusion. Any Grade: 13%. Grade 3 or Higher: 2%. 

Renal and Urinary Disorders  
Renal insufficiency. Any Grade: 12%. Grade 3 or Higher: 5%. 
 
Vascular Disorders  
Hypotension Refer to footnote r. Any Grade: 57%. Grade 3 or Higher: 15%. 
Hypertension. Any Grade: 15%. Grade 3 or Higher: 6%.
Thrombosis Refer to footnote s. Any Grade: 10%. Grade 3 or Higher: 1%. 

Footnotes:                                                                                                                 
The following events were also counted in the incidence of CRS: tachycardia, arrhythmia, fever, chills, hypoxia, renal insufficiency, and hypotension.                     
a. Tachycardia includes tachycardia, sinus tachycardia.
b. Arrhythmia includes arrhythmia, atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block right, electrocardiogram QT prolonged, extra-systoles, heart rate irregular, supraventricular extra systoles, supraventricular tachycardia, ventricular arrhythmia, ventricular tachycardia.
c. Abdominal pain includes abdominal pain, abdominal pain lower, abdominal pain upper.
d. Fever includes fever, febrile neutropenia.
e. Fatigue includes fatigue, malaise.
f. Edema includes face edema, generalized edema, local swelling, localized edema, edema, edema genital, edema peripheral, periorbital edema, peripheral swelling, scrotal edema.
g. Hypogammaglobulinemia includes hypogammaglobulinemia, blood immunoglobulin D decreased, blood immunoglobulin G decreased. 
h. Motor dysfunction includes muscle spasms, muscular weakness.
i. Pain in extremity includes pain not otherwise specified, pain in extremity.
j. Encephalopathy includes cognitive disorder, confusional state, depressed level of consciousness, disturbance in attention, encephalopathy, hypersomnia, leukoencephalopathy, memory impairment, mental status changes, paranoia, somnolence, stupor. 
k. Headache includes headache, head discomfort, sinus headache, procedural headache.
l. Dizziness includes dizziness, presyncope, syncope.
m. Aphasia includes aphasia, dysphasia.
n. Delirium includes agitation, delirium, delusion, disorientation, hallucination, hyperactivity, irritability, restlessness.
o. Hypoxia includes hypoxia, oxygen saturation decreased.
p. Cough includes cough, productive cough, upper-airway cough syndrome.
q. Dyspnea includes acute respiratory failure, dyspnea, orthopnea, respiratory distress.
r. Hypotension includes diastolic hypotension, hypotension, orthostatic hypotension.
s. Thrombosis includes deep vein thrombosis, embolism, embolism venous, pulmonary embolism, splenic infarction, splenic vein thrombosis, subclavian vein thrombosis, thrombosis, thrombosis in device.

Febrile neutropenia: Febrile neutropenia in Any Grade is 31%. Febrile neutropenia in Grade 3 or higher is 31%.
Tachycardia (Refer to footnote a). Tachycardia in Any Grade is 43%. Tachycardia in Grade 3 or higher is 2%.
Arrhythmia (Refer to footnote b). Arrhythmia in Any Grade is 14%. Arrhythmia in Grade 3 or higher is 3%.
Diarrhea (Refer to footnote c). Diarrhea in Any Grade is 42%. Diarrhea in Grade 3 or higher is 3%.
Nausea: Nausea in Any Grade is 40%. Nausea in Grade 3 or higher is 2%.
Abdominal pain (Refer to footnote d). Abdominal pain in Any Grade is 20%. Abdominal pain in Grade 3 or higher is 4%.
Constipation: Constipation in Any Grade is 20%. Constipation in Grade 3 or higher is 0%.
Vomiting: Vomiting in Any Grade is 20%. Vomiting in Grade 3 or higher is 0%.
Dry Mouth: Dry Mouth in Any Grade is 10%. Dry Mouth in Grade 3 or higher is 0%.
Fever (Refer to footnote e). Fever in Any Grade is 93%. Fever in Grade 3 or higher is 9%.
Fatigue (Refer to footnote f ). Fatigue in Any Grade is 52%. Fatigue in Grade 3 or higher is 7%.
Chills: Chills in Any Grade is 28%. Chills in Grade 3 or higher is 1%.
Edema (Refer to footnote g). Edema in Any Grade is 23%. Edema in Grade 3 or higher is 1%.
Cytokine release syndrome: Cytokine release syndrome in Any Grade is 92%. Cytokine release syndrome in Grade 3 or higher is 7%.
Hypogammaglobulinemia: Hypogammaglobulinemia  in Any Grade is 11%. Hypogammaglobulinemia  in Grade 3 or higher is 0%.
Infections with pathogen unspecified: Infections with pathogen unspecified in Any Grade is 25%. Infections with pathogen unspecified in Grade 3 or higher is 8%.
Viral infections: Viral infections in Any Grade is 15%. Viral infections in Grade 3 or higher is 4%.
Bacterial infections: Bacterial infections in Any Grade is 10%. Bacterial infections in Grade 3 or higher is 5%.
Fungal infections: Fungal infections in Any Grade is 10%. Fungal infections in Grade 3 or higher is 1%.
Decreased appetite: Decreased appetite in Any Grade is 24%. Decreased appetite in Grade 3 or higher is 4%.
Musculoskeletal pain (Refer to footnote h). Musculoskeletal pain in Any Grade is 40%. Musculoskeletal pain in Grade 3 or higher is 1%.
Motor dysfunction (Refer to footnote i). Motor dysfunction in Any Grade is 15%. Motor dysfunction in Grade 3 or higher is 4%.
Encephalopathy (Refer to footnote j). Encephalopathy in Any Grade is 46%. Encephalopathy in Grade 3 or higher is 18%.
Headache (Refer to footnote k). Headache in Any Grade is 41%. Headache in Grade 3 or higher is 3%.
Tremor: Tremor in Any Grade is 25%. Tremor in Grade 3 or higher is 1%.
Dizziness (Refer to footnote l). Dizziness in Any Grade is 25%. Dizziness in Grade 3 or higher is 4%.
Aphasia: Aphasia in Any Grade is 20%. Aphasia in Grade 3 or higher is 7%.
Neuropathy peripheral (Refer to footnote m). Neuropathy peripheral in Any Grade is 11%. Neuropathy peripheral in Grade 3 or higher is 2%.
Insomnia (Refer to footnote n). Insomnia in Any Grade is 13%. Insomnia in Grade 3 or higher is 0%.
Delirium (Refer to footnote o). Delirium in Any Grade is 12%. Delirium in Grade 3 or higher is 4%.
Renal insufficiency (Refer to footnote p). Renal insufficiency in Any Grade is 11%. Renal insufficiency in Grade 3 or higher is 2%.
Cough (Refer to footnote q). Cough in Any Grade is 27%. Cough in Grade 3 or higher is 1%.
Hypoxia: Hypoxia in Any Grade is 21%. Hypoxia in Grade 3 or higher is 9%.
Rash (Refer to footnote r). Rash in Any Grade is 17%. Rash in Grade 3 or higher is 1%.
Hypotension (Refer to footnote s). Hypotension in Any Grade is 47%. Hypotension in Grade 3 or higher is 11%.

" style="width:96%"><thead><tr><td rowspan="2"><p><strong>Adverse Reaction</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Yescarta</strong></p><p><strong>N = 168</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Any Grade (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade 3 or Higher (%)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>31</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Cardiac Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia <sup>a</sup></p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia <sup>b</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Gastrointestinal Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea <sup>c</sup></p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain <sup>d</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dry Mouth</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>General Disorders and Administration Site Conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>Fever <sup>e</sup></p></td><td style="vertical-align:top"><p>93</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue <sup>f</sup></p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Edema <sup>g</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Immune System Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Cytokine release syndrome</p></td><td style="vertical-align:top"><p>92</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Hypogammaglobulinemia</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Infections and Infestations</em></p></td></tr><tr><td style="vertical-align:top"><p>Infections with pathogen unspecified</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Viral infections</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial infections</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Fungal infections</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Metabolism and Nutrition Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Musculoskeletal and Connective Tissue Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain <sup>h</sup></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Motor dysfunction <sup>i</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nervous System Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Encephalopathy <sup>j</sup></p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>18</p></td></tr><tr><td style="vertical-align:top"><p>Headache <sup>k</sup></p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness <sup>l</sup></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Aphasia</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Neuropathy peripheral <sup>m</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Psychiatric Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia <sup>n</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Delirium <sup>o</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Renal and Urinary Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency <sup>p</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Respiratory, Thoracic and Mediastinal Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Cough <sup>q</sup></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Hypoxia</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Skin and Subcutaneous Tissue Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Rash <sup>r</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Vascular Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension <sup>s</sup></p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>11</p></td></tr></tbody></table><p>The following events were also counted in the incidence of CRS: coagulopathy, tachycardia, arrhythmia, cardiac failure, diarrhea, nausea, vomiting, fever, fatigue, chills, edema, decreased appetite, musculoskeletal pain, headache, tremor, dizziness, renal insufficiency, cough, hypoxia, dyspnea, pleural effusion, respiratory failure, rash, hypotension, and hypertension.&nbsp;</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia includes tachycardia, sinus tachycardia.&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Arrhythmia includes arrhythmia, atrial fibrillation, bradycardia, electrocardiogram QT prolonged, extrasystoles, sinus bradycardia, supraventricular extrasystoles, supraventricular tachycardia, ventricular extrasystoles, ventricular tachycardia.&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea includes diarrhea, colitis.&nbsp;</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain includes abdominal pain, abdominal discomfort, abdominal pain lower, abdominal pain upper, dyspepsia.&nbsp;</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp; Fever includes pyrexia.&nbsp;</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue includes fatigue, asthenia, malaise.&nbsp;</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp; Edema includes edema, face edema, fluid overload, generalized edema, hypervolemia,&nbsp;localized edema, edema genital, edema peripheral, periorbital edema, peripheral swelling, pulmonary edema.</p><p>h.&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal pain includes musculoskeletal pain, arthralgia, arthritis, back pain, bone pain, flank pain, groin pain, musculoskeletal chest pain, myalgia, neck pain, non-cardiac chest pain, pain in extremity.&nbsp;&nbsp;</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Motor dysfunction includes muscle contractions involuntary, muscle spasms, muscle twitching, muscular weakness.&nbsp;</p><p>j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy includes encephalopathy, altered state of consciousness, amnesia, apraxia, bradyphrenia, cognitive disorder, confusional state, depressed level of consciousness, disturbance in attention, dysarthria, dysgraphia, dyspraxia, lethargy, loss of consciousness, memory impairment, mental impairment, mental status changes, metabolic encephalopathy, slow speech, somnolence, toxic encephalopathy.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache includes headache and tension headache.</p><p>l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness includes dizziness, dizziness postural, presyncope, syncope, vertigo.&nbsp;</p><p>m.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuropathy peripheral includes hypoesthesia, lumbar radiculopathy, neuropathy peripheral, paresthesia, peroneal nerve palsy, sciatica.&nbsp;</p><p>n.&nbsp;&nbsp;&nbsp;&nbsp; Insomnia includes insomnia and sleep deficit.</p><p>o.&nbsp;&nbsp;&nbsp;&nbsp; Delirium includes delirium, agitation, delusion, disorientation, hallucination, irritability, restlessness.&nbsp;</p><p>p.&nbsp;&nbsp;&nbsp;&nbsp; Renal insufficiency includes acute kidney injury, blood creatinine increased, chronic kidney disease.</p><p>q.&nbsp;&nbsp;&nbsp;&nbsp; Cough includes cough, productive cough, upper-airway cough syndrome.&nbsp;</p><p>r.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash includes rash, dermatitis, dermatitis allergic, dermatitis bullous, drug eruption, erythema, pruritus, rash macular, rash maculo-papular, rash pruritic, urticaria.&nbsp;</p><p>s.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension includes hypotension, capillary leak syndrome, orthostatic hypotension.&nbsp;</p><p><strong>&nbsp;</strong></p><p>Other clinically important adverse reactions that occurred in less than 10% of patients treated with Yescarta include the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Blood and lymphatic system disorders:</em> Coagulopathy (9%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Cardiac disorders:</em> Cardiac failure (1%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Eye Disorders:</em> Visual impairment (7%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Infections and infestations:</em> Pneumonia (8%), Sepsis (4%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Nervous system disorders:</em> Ataxia (6%), seizure (3%), myoclonus (2%), facial paralysis (2%), paresis (2%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Respiratory, thoracic and mediastinal disorders:</em> Dyspnea (8%), pleural effusion (6%), respiratory failure (2%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Vascular disorders: </em>Hypertension (9%), thrombosis (7%)</p><p>&nbsp;</p><p>Laboratory abnormalities:</p><p>&nbsp;</p><p>Table 4.&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or 4 Laboratory Abnormalities Occurring in &ge; 10% of Patients in ZUMA-7 Following Treatment with Yescarta<sup>1</sup><sup> </sup>(N = 168)</p><table border="1" cellspacing="0" cellpadding="0" summary="Table 6. Grade 3 or 4 Laboratory Abnormalities Occurring in ≥ 10% of Patients in ZUMA-5 Following Treatment with YESCARTA (N = 146). 
                                                                                                                          Neutropenia. Grades 3 or 4: 92%                                                                 Leukopenia. Grades 3 or 4: 92%                                                      Thrombocytopenia. Grades 3 or 4: 35%                                                          
Anemia. Grades 3 or 4: 30%
Hypophosphatemia. Grades 3 or 4: 25%
Lymphopenia. Grades 3 or 4: 23% 
Hyponatremia. Grades 3 or 4: 10% 
Hyperglycemia. Grade 3 or 4: 10%
Hyperuricemia. Grades 3 or 4: 10%
Hypocalcemia. Grades 3 or 4: 10%
" style="width:413px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Laboratory Abnormality</strong></p></td><td style="vertical-align:bottom"><p><strong>Yescarta</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Grades 3 or 4 (%) </strong></p></td></tr><tr><td><p>Leukocyte decrease</p></td><td><p>95</p></td></tr><tr><td><p>Neutrophil decrease</p></td><td><p>94</p></td></tr><tr><td><p>Lymphocyte decrease</p></td><td><p>94</p></td></tr><tr><td><p>Hemoglobin decrease</p></td><td><p>40</p></td></tr><tr><td><p>Platelet decrease</p></td><td><p>26</p></td></tr><tr><td><p>Sodium decrease</p></td><td><p>12</p></td></tr><tr><td><p>Glucose increase</p></td><td><p>11</p></td></tr></tbody></table><p><sup>1</sup>Baseline lab values were assessed prior to lymphodepleting chemotherapy</p><p><em>&nbsp;</em></p><p><em>ZUMA-1</em></p><p>The safety of Yescarta was evaluated in ZUMA-1, a study in which 108 patients with relapsed or refractory LBCL received CD19-positive CAR T cells based on a recommended dose which was weight-based (see section 5.1). Patients with a history of CNS disorders (such as seizures or cerebrovascular ischemia) or autoimmune disease requiring systemic immunosuppression were ineligible. The median age of the study population was 58 years (range: 23 to 76 years); 68% were male. The baseline Eastern Cooperative Oncology Group (ECOG) performance status was 0 in 43% of patients and 1 in 57% of patients.</p><p>The most common adverse reactions (incidence &ge; 20%) included CRS, fever, hypotension, encephalopathy, tachycardia, fatigue, headache, decreased appetite, chills, diarrhea, febrile neutropenia, infections with pathogen unspecified, nausea, hypoxia, tremor, cough, vomiting, dizziness, constipation, and cardiac arrhythmias. Serious adverse reactions occurred in 52% of patients. The most common serious adverse reactions (&gt; 2%) included encephalopathy, fever, lung infection, febrile neutropenia, cardiac arrhythmia, cardiac failure, urinary tract infection, renal insufficiency, aphasia, cardiac arrest, <em>Clostridium difficile</em> infection, delirium, hypotension, and hypoxia.</p><p>&nbsp;</p><p>The most common (&ge; 10%) Grade 3 or higher reactions included febrile neutropenia, fever, CRS, encephalopathy, infections with pathogen unspecified, hypotension, hypoxia, and lung infections.</p><p>&nbsp;</p><p>Forty-five percent (49/108) of patients received tocilizumab after infusion of Yescarta.</p><p>&nbsp;</p><p>Table 5 summarizes non-laboratory adverse reactions that occurred in &ge; 10% of patients treated with Yescarta, and Table&nbsp;6 describes the laboratory abnormalities of Grade 3 or 4 that occurred in &ge; 10% of patients.</p><p><strong>&nbsp;</strong></p><p><strong>Table 5.</strong>&nbsp;&nbsp;&nbsp; <strong>Adverse Reactions Observed in &ge; 10% of Patients Treated with Yescarta in ZUMA-1 (N = 108)</strong></p><table border="0" cellspacing="0" cellpadding="0" summary="Table 3. Summary of Adverse Reactions Observed in at Least 10% of Patients Treated with Yescarta in ZUMA-1 (N=108)
Blood and Lymphatic System Disorders  
Adverse Reaction. Febrile neutropenia. Any Grade: 34%. Grade 3 or Higher: 31%.
Cardiac Disorders  
Adverse Reaction. Tachycardias Refer to footnote a. Any Grade: 57%. Grade 3 or Higher: 2%.
Adverse Reaction. Arrhythmias Refer to footnote b. Any Grade: 23%. Grade 3 or Higher: 7%.

Gastrointestinal Disorders  
Adverse Reaction. Diarrhea. Any Grade: 38%. Grade 3 or Higher: 4%.      Adverse Reaction. Nausea. Any Grade: 34%. Grade 3 or Higher: 0%.        Adverse Reaction. Vomiting. Any Grade: 26%. Grade 3 or Higher: 1%. 
Adverse Reaction. Constipation. Any Grade: 23%. Grade 3 or Higher: 0%.
Adverse Reaction. Abdominal pain Refer to footnote c. Any Grade: 14%. Grade 3 or Higher: 1%.
Adverse Reaction. Dry mouth. Any Grade: 11%. Grade 3 or Higher: 0%.

General Disorders and Administration Site Conditions  
Adverse Reaction. Fever. Refer to footnote d. Any Grade: 86%. Grade 3 or Higher: 16%.
Adverse Reaction. Fatigue Refer to footnote e. Any Grade: 46%. Grade 3 or Higher: 3%.
Adverse Reaction. Chills. Any Grade: 40%. Grade 3 or Higher: 0%.
Adverse Reaction. Edema Refer to footnote f. Any Grade: 19%. Grade 3 or Higher: 1%.

Immune System Disorders  
Adverse Reaction. Cytokine release syndrome. Any Grade: 94%. Grade 3 or Higher: 13%.
Adverse Reaction. Hypogammaglobulinemia Refer to footnote g. Any Grade: 15%. Grade 3 or Higher: 0%.

Infections and Infestations  
Adverse Reaction. Infection with pathogen unspecified. Any Grade: 26%. Grade 3 or Higher: 16%. 
Adverse Reaction. Viral infections. Any Grade: 16%. Grade 3 or Higher: 4%.
Adverse Reaction. Bacterial infections. Any Grade: 13%. Grade 3 or Higher: 9%.
                                                                                                                                 Investigations                                                                                              Adverse Reaction. Decreased appetite. Any Grade 44%. Grade 3 or Higher: 2%.                                                                                                               Adverse Reaction. Weight decreased. Any Grade 16%. Grade 3 or Higher: 0%.                                                                                                               Adverse Reaction. Dehydration. Any Grade 11%. Grade 3 or Higher: 3%.          
                                                                                                             Musculoskeletal and Connective Tissue Disorders  
Adverse Reaction. Motor dysfunction. Refer to footnote h. Any Grade: 19%. Grade 3 or Higher: 1%.
Adverse Reaction. Pain in extremity. Refer to footnote i. Any Grade: 17%. Grade 3 or Higher: 2%.
Adverse Reaction. Back pain. Any Grade: 15%. Grade 3 or Higher: 1%.
Adverse Reaction. Muscle pain. Any Grade: 14%. Grade 3 or Higher: 1%.
Adverse Reaction. Arthralgia. Any Grade: 10%. Grade 3 or Higher: 0%.                   
                                                                                                                          Nervous System Disorders  
Adverse Reaction. Encephalopathy Refer to footnote j. Any Grade: 57%. Grade 3 or Higher: 29%. 
Adverse Reaction. Headache Refer to footnote k. Any Grade: 45%. Grade 3 or Higher: 1%.
Adverse Reaction. Tremor. Any Grade: 31%. Grade 3 or Higher: 2%.        Adverse Reaction. Dizziness Refer to footnote l.  Any Grade: 21%. Grade 3 or Higher: 1%.                                                                                                       Adverse Reaction. Aphasia Refer to footnote m. Any Grade: 18%. Grade 3 or Higher: 6%. 

Psychiatric Disorders  
Adverse Reaction. Delirium Refer to footnote m. Any Grade:17%. Grade 3 or Higher: 6%.                                                                                                                       
                                                                                                                    Respiratory, Thoracic and Mediastinal Disorders  
Adverse Reaction. Hypoxia. Refer to footnote o. Any Grade: 32%. Grade 3 or Higher: 11%. 
Adverse Reaction. Cough Refer to footnote p. Any Grade: 30%. Grade 3 or Higher: 0%.
Adverse Reaction. Dyspnea Refer to footnote q. Any Grade: 19%. Grade 3 or Higher: 3%. 
Adverse Reaction. Pleural effusion. Any Grade: 13%. Grade 3 or Higher: 2%. 

Renal and Urinary Disorders  
Adverse Reaction. Renal insufficiency. Any Grade: 12%. Grade 3 or Higher: 5%. 
 
Vascular Disorders  
Adverse Reaction. Hypotension Refer to footnote r. Any Grade: 57%. Grade 3 or Higher: 15%. 
Adverse Reaction. Hypertension. Any Grade: 15%. Grade 3 or Higher: 6%.
Adverse Reaction. Thrombosis Refer to footnote s. Any Grade: 10%. Grade 3 or Higher: 1%. 

Footnotes:                                                                                                                 The following events were also counted in the incidence of CRS: tachycardia, arrhythmia, fever, chills, hypoxia, renal insufficiency, and hypotension.                     
                                                                                                                                      a. Tachycardia includes tachycardia, sinus tachycardia.
b. Arrhythmia includes arrhythmia, atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block right, electrocardiogram QT prolonged, extra-systoles, heart rate irregular, supraventricular extra systoles, supraventricular tachycardia, ventricular arrhythmia, ventricular tachycardia.
c. Abdominal pain includes abdominal pain, abdominal pain lower, abdominal pain upper.
d. Fever includes fever, febrile neutropenia.
e. Fatigue includes fatigue, malaise.
f. Edema includes face edema, generalized edema, local swelling, localized edema, edema, edema genital, edema peripheral, periorbital edema, peripheral swelling, scrotal edema.
g. Hypogammaglobulinemia includes hypogammaglobulinemia, blood immunoglobulin D decreased, blood immunoglobulin G decreased. 
h. Motor dysfunction includes muscle spasms, muscular weakness.
i. Pain in extremity includes pain not otherwise specified, pain in extremity.
j. Encephalopathy includes cognitive disorder, confusional state, depressed level of consciousness, disturbance in attention, encephalopathy, hypersomnia, leukoencephalopathy, memory impairment, mental status changes, paranoia, somnolence, stupor. 
k. Headache includes headache, head discomfort, sinus headache, procedural headache.
l. Dizziness includes dizziness, presyncope, syncope.
m. Aphasia includes aphasia, dysphasia.
n. Delirium includes agitation, delirium, delusion, disorientation, hallucination, hyperactivity, irritability, restlessness.
o. Hypoxia includes hypoxia, oxygen saturation decreased.
p. Cough includes cough, productive cough, upper-airway cough syndrome.
q. Dyspnea includes acute respiratory failure, dyspnea, orthopnea, respiratory distress.
r. Hypotension includes diastolic hypotension, hypotension, orthostatic hypotension.
s. Thrombosis includes deep vein thrombosis, embolism, embolism venous, pulmonary embolism, splenic infarction, splenic vein thrombosis, subclavian vein thrombosis, thrombosis, thrombosis in device.
" style="width:636px"><thead><tr><td style="vertical-align:bottom"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:bottom"><p><strong>Any Grade (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade 3 or Higher (%)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><em>Blood and Lymphatic System Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>31</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Cardiac Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia <sup>a</sup></p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia <sup>b</sup></p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Gastrointestinal Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain <sup>c</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>General Disorders and Administration Site Conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>Fever <sup>d</sup></p></td><td style="vertical-align:top"><p>86</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue <sup>e</sup></p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Edema <sup>f</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Immune System Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Cytokine release syndrome</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>Hypogammaglobulinemia <sup>g</sup></p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Infections and Infestations</em></p></td></tr><tr><td style="vertical-align:top"><p>Infections with pathogen unspecified</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Viral infections</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial infections</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Investigations</em></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Musculoskeletal and Connective Tissue Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Motor dysfunction <sup>h</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity <sup>i</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Muscle pain</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nervous System Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Encephalopathy <sup>j</sup></p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>29</p></td></tr><tr><td style="vertical-align:top"><p>Headache <sup>k</sup></p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness <sup>l</sup></p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Aphasia <sup>m</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Psychiatric Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Delirium <sup>n</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Respiratory, Thoracic and Mediastinal Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Hypoxia <sup>o</sup></p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>11</p></td></tr><tr><td style="vertical-align:top"><p>Cough <sup>p</sup></p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea <sup>q</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td style="vertical-align:top"><p>Pleural effusion</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Renal and Urinary Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Vascular Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension <sup>r</sup></p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>15</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Thrombosis <sup>s</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" summary="Table 3. Summary of Adverse Reactions Observed in at Least 10% of Patients Treated with Yescarta in ZUMA-1 (N=108)
Blood and Lymphatic System Disorders  
Adverse Reaction. Febrile neutropenia. Any Grade: 34%. Grade 3 or Higher: 31%.
Cardiac Disorders  
Adverse Reaction. Tachycardias Refer to footnote a. Any Grade: 57%. Grade 3 or Higher: 2%.
Adverse Reaction. Arrhythmias Refer to footnote b. Any Grade: 23%. Grade 3 or Higher: 7%.

Gastrointestinal Disorders  
Adverse Reaction. Diarrhea. Any Grade: 38%. Grade 3 or Higher: 4%.      Adverse Reaction. Nausea. Any Grade: 34%. Grade 3 or Higher: 0%.        Adverse Reaction. Vomiting. Any Grade: 26%. Grade 3 or Higher: 1%. 
Adverse Reaction. Constipation. Any Grade: 23%. Grade 3 or Higher: 0%.
Adverse Reaction. Abdominal pain Refer to footnote c. Any Grade: 14%. Grade 3 or Higher: 1%.
Adverse Reaction. Dry mouth. Any Grade: 11%. Grade 3 or Higher: 0%.

General Disorders and Administration Site Conditions  
Adverse Reaction. Fever. Refer to footnote d. Any Grade: 86%. Grade 3 or Higher: 16%.
Adverse Reaction. Fatigue Refer to footnote e. Any Grade: 46%. Grade 3 or Higher: 3%.
Adverse Reaction. Chills. Any Grade: 40%. Grade 3 or Higher: 0%.
Adverse Reaction. Edema Refer to footnote f. Any Grade: 19%. Grade 3 or Higher: 1%.

Immune System Disorders  
Adverse Reaction. Cytokine release syndrome. Any Grade: 94%. Grade 3 or Higher: 13%.
Adverse Reaction. Hypogammaglobulinemia Refer to footnote g. Any Grade: 15%. Grade 3 or Higher: 0%.

Infections and Infestations  
Adverse Reaction. Infection with pathogen unspecified. Any Grade: 26%. Grade 3 or Higher: 16%. 
Adverse Reaction. Viral infections. Any Grade: 16%. Grade 3 or Higher: 4%.
Adverse Reaction. Bacterial infections. Any Grade: 13%. Grade 3 or Higher: 9%.
                                                                                                                                 Investigations                                                                                              Adverse Reaction. Decreased appetite. Any Grade 44%. Grade 3 or Higher: 2%.                                                                                                               Adverse Reaction. Weight decreased. Any Grade 16%. Grade 3 or Higher: 0%.                                                                                                               Adverse Reaction. Dehydration. Any Grade 11%. Grade 3 or Higher: 3%.          
                                                                                                             Musculoskeletal and Connective Tissue Disorders  
Adverse Reaction. Motor dysfunction. Refer to footnote h. Any Grade: 19%. Grade 3 or Higher: 1%.
Adverse Reaction. Pain in extremity. Refer to footnote i. Any Grade: 17%. Grade 3 or Higher: 2%.
Adverse Reaction. Back pain. Any Grade: 15%. Grade 3 or Higher: 1%.
Adverse Reaction. Muscle pain. Any Grade: 14%. Grade 3 or Higher: 1%.
Adverse Reaction. Arthralgia. Any Grade: 10%. Grade 3 or Higher: 0%.                   
                                                                                                                          Nervous System Disorders  
Adverse Reaction. Encephalopathy Refer to footnote j. Any Grade: 57%. Grade 3 or Higher: 29%. 
Adverse Reaction. Headache Refer to footnote k. Any Grade: 45%. Grade 3 or Higher: 1%.
Adverse Reaction. Tremor. Any Grade: 31%. Grade 3 or Higher: 2%.        Adverse Reaction. Dizziness Refer to footnote l.  Any Grade: 21%. Grade 3 or Higher: 1%.                                                                                                       Adverse Reaction. Aphasia Refer to footnote m. Any Grade: 18%. Grade 3 or Higher: 6%. 

Psychiatric Disorders  
Adverse Reaction. Delirium Refer to footnote m. Any Grade:17%. Grade 3 or Higher: 6%.                                                                                                                       
                                                                                                                    Respiratory, Thoracic and Mediastinal Disorders  
Adverse Reaction. Hypoxia. Refer to footnote o. Any Grade: 32%. Grade 3 or Higher: 11%. 
Adverse Reaction. Cough Refer to footnote p. Any Grade: 30%. Grade 3 or Higher: 0%.
Adverse Reaction. Dyspnea Refer to footnote q. Any Grade: 19%. Grade 3 or Higher: 3%. 
Adverse Reaction. Pleural effusion. Any Grade: 13%. Grade 3 or Higher: 2%. 

Renal and Urinary Disorders  
Adverse Reaction. Renal insufficiency. Any Grade: 12%. Grade 3 or Higher: 5%. 
 
Vascular Disorders  
Adverse Reaction. Hypotension Refer to footnote r. Any Grade: 57%. Grade 3 or Higher: 15%. 
Adverse Reaction. Hypertension. Any Grade: 15%. Grade 3 or Higher: 6%.
Adverse Reaction. Thrombosis Refer to footnote s. Any Grade: 10%. Grade 3 or Higher: 1%. 

Footnotes:                                                                                                                 The following events were also counted in the incidence of CRS: tachycardia, arrhythmia, fever, chills, hypoxia, renal insufficiency, and hypotension.                     
                                                                                                                                      a. Tachycardia includes tachycardia, sinus tachycardia.
b. Arrhythmia includes arrhythmia, atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block right, electrocardiogram QT prolonged, extra-systoles, heart rate irregular, supraventricular extra systoles, supraventricular tachycardia, ventricular arrhythmia, ventricular tachycardia.
c. Abdominal pain includes abdominal pain, abdominal pain lower, abdominal pain upper.
d. Fever includes fever, febrile neutropenia.
e. Fatigue includes fatigue, malaise.
f. Edema includes face edema, generalized edema, local swelling, localized edema, edema, edema genital, edema peripheral, periorbital edema, peripheral swelling, scrotal edema.
g. Hypogammaglobulinemia includes hypogammaglobulinemia, blood immunoglobulin D decreased, blood immunoglobulin G decreased. 
h. Motor dysfunction includes muscle spasms, muscular weakness.
i. Pain in extremity includes pain not otherwise specified, pain in extremity.
j. Encephalopathy includes cognitive disorder, confusional state, depressed level of consciousness, disturbance in attention, encephalopathy, hypersomnia, leukoencephalopathy, memory impairment, mental status changes, paranoia, somnolence, stupor. 
k. Headache includes headache, head discomfort, sinus headache, procedural headache.
l. Dizziness includes dizziness, presyncope, syncope.
m. Aphasia includes aphasia, dysphasia.
n. Delirium includes agitation, delirium, delusion, disorientation, hallucination, hyperactivity, irritability, restlessness.
o. Hypoxia includes hypoxia, oxygen saturation decreased.
p. Cough includes cough, productive cough, upper-airway cough syndrome.
q. Dyspnea includes acute respiratory failure, dyspnea, orthopnea, respiratory distress.
r. Hypotension includes diastolic hypotension, hypotension, orthostatic hypotension.
s. Thrombosis includes deep vein thrombosis, embolism, embolism venous, pulmonary embolism, splenic infarction, splenic vein thrombosis, subclavian vein thrombosis, thrombosis, thrombosis in device.
"><tbody><tr><td style="vertical-align:top"><p>The following events were also counted in the incidence of CRS: tachycardia, arrhythmia, fever, chills, hypoxia, renal insufficiency, and hypotension.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia includes tachycardia, sinus tachycardia.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arrhythmia includes arrhythmia, atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block right, electrocardiogram QT prolonged, extra-systoles, heart rate irregular, supraventricular extra systoles, supraventricular tachycardia, ventricular arrhythmia, ventricular tachycardia.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain includes abdominal pain, abdominal pain lower, abdominal pain upper.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever includes fever, febrile neutropenia.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue includes fatigue, malaise.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Edema includes face edema, generalized edema, local swelling, localized edema, edema, edema genital, edema peripheral, periorbital edema, peripheral swelling, scrotal edema.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinemia includes hypogammaglobulinemia, blood immunoglobulin D decreased, blood immunoglobulin G decreased.</p><p>h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Motor dysfunction includes muscle spasms, muscular weakness.</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in extremity includes pain not otherwise specified, pain in extremity.</p><p>j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy includes cognitive disorder, confusional state, depressed level of consciousness, disturbance in attention, encephalopathy, hypersomnia, leukoencephalopathy, memory impairment, mental status changes, paranoia, somnolence, stupor.</p><p>k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache includes headache, head discomfort, sinus headache, procedural headache.</p><p>l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness includes dizziness, presyncope, syncope.</p><p>m.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aphasia includes aphasia, dysphasia.</p><p>n.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delirium includes agitation, delirium, delusion, disorientation, hallucination, hyperactivity, irritability, restlessness.</p><p>o.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypoxia includes hypoxia, oxygen saturation decreased.</p><p>p.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough includes cough, productive cough, upper-airway cough syndrome.</p><p>q.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnea includes acute respiratory failure, dyspnea, orthopnea, respiratory distress.</p><p>r.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension includes diastolic hypotension, hypotension, orthostatic hypotension.</p><p>s.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombosis includes deep vein thrombosis, embolism, embolism venous, pulmonary embolism, splenic infarction, splenic vein thrombosis, subclavian vein thrombosis, thrombosis, thrombosis in device.</p></td></tr></tbody></table><p>&nbsp;</p><p>Other clinically important adverse reactions that occurred in less than 10% of patients treated with Yescarta include the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Blood and lymphatic system disorders:</em> Coagulopathy (2%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Cardiac disorders:</em> Cardiac failure (6%), cardiac arrest (4%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Immune system disorders:</em> Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) (1%), hypersensitivity (1%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Infections and infestations disorders:</em> Fungal infections (5%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Nervous system disorders:</em> Ataxia (6%), seizure (4%), dyscalculia (2%), myoclonus (2%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Respiratory, thoracic and mediastinal disorders:</em> Pulmonary edema (9%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Skin and subcutaneous tissue disorders:</em> Rash (9%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Vascular disorders:</em> Capillary leak syndrome (3%)</p><p>&nbsp;</p><p>Laboratory abnormalities:</p><p>&nbsp;</p><p>Table 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or 4 Laboratory Abnormalities Occurring in &ge; 10% of Patients in ZUMA-1 Following Treatment with Yescarta<sup>1</sup> (N = 108)</p><table border="1" cellspacing="0" cellpadding="0" summary="Table 4. Grade 3 or 4 Laboratory Abnormalities Occurring in ≥ 10% of Patients in ZUMA-1 Following Treatment with YESCARTA (N = 108). 
                                                                                                                          Lymphopenia. Grades 3 or 4: 100%                                                           Leukopenia. Grades 3 or 4: 96%
Neutropenia. Grades 3 or 4: 93%
Anemia. Grades 3 or 4: 66%
Thrombocytopenia. Grades 3 or 4: 58%
Hypophosphatemia. Grades 3 or 4: 50%
Hypocalcemia. Grades 3 or 4: 19%
Uric acid increased. Grades 3 or 4: 13%
Direct bilirubin increased. Grades 3 or 4: 13%
Hypokalemia. Grades 3 or 4: 10%
Alanine aminotransferase increased. Grades 3 or 4: 10%
" style="width:413px"><tbody><tr><td><p><strong>Laboratory Abnormality</strong></p></td><td style="vertical-align:bottom"><p><strong>Grades 3 or 4 (%)</strong></p></td></tr><tr><td><p>Lymphocyte decrease</p></td><td><p>96</p></td></tr><tr><td><p>Leukocyte decrease</p></td><td><p>96</p></td></tr><tr><td><p>Neutrophil decrease</p></td><td><p>92</p></td></tr><tr><td><p>Hemoglobin decrease</p></td><td><p>60</p></td></tr><tr><td><p>Platelet decrease</p></td><td><p>56</p></td></tr><tr><td><p>Phosphate decrease</p></td><td><p>52</p></td></tr><tr><td><p>Sodium decrease</p></td><td><p>19</p></td></tr><tr><td style="vertical-align:top"><p>Albumin decrease</p></td><td style="vertical-align:top"><p>19</p></td></tr><tr><td><p>Direct bilirubin increased</p></td><td><p>14</p></td></tr><tr><td><p>Uric acid increased</p></td><td><p>13</p></td></tr><tr><td><p>Potassium decrease</p></td><td><p>11</p></td></tr></tbody></table><p><sup>1</sup>Baseline lab values were assessed prior to lymphodepleting chemotherapy.</p><p>&nbsp;</p><p>The safety and efficacy of Yescarta was evaluated in two subsequent cohorts of LBCL patients. The first subsequent, open label, safety management cohort in ZUMA-1 evaluated the safety and efficacy of Yescarta with the use of tocilizumab and/or corticosteroid and prophylactic levetiracetam (750mg PO or IV twice daily) for Grade 1 CRS or neurologic events (see Tables 1 and 2). A total of 46 patients with relapsed or refractory LBCL were enrolled and 41 patients were treated with Yescarta. Of the remaining 5 patients who were not treated, 2 patients died prior to receiving Yescarta and 3 patients were ineligible due to disease progression. Twenty-eight patients (68%) treated with Yescarta received bridging therapy between leukapheresis and lymphodepleting chemotherapy. Thirty-two patients (78%) treated with Yescarta received tocilizumab and/or corticosteroid for CRS and/or neurologic events. Fifteen of 36 with Grade 1 CRS and 21 of 24 patients with Grade 2 CRS received tocilizumab and/or corticosteroids. Among patients who received treatment for Grade 1 or Grade 2 CRS, most patients (13 of 15 and 19 of 21 patients, respectively) received both tocilizumab and corticosteroids. Most patients received 1 or 2 doses of each drug. Ten of 27 patients with Grade 1 and 7 of 15 patients with Grade 2 neurologic events received corticosteroids alone or in combination with tocilizumab.</p><p>&nbsp;</p><p>The second subsequent, open label, safety management cohort in ZUMA-1 evaluated the safety and efficacy of Yescarta with the use of prophylactic corticosteroids (oral dexamethasone 10 mg once daily for 3 days, starting prior to Yescarta infusion on Day 0) and prophylactic levetiracetam (750 mg PO or IV) <em>(see section 4.4)</em>.</p><p><u>&nbsp;</u></p><p><u>Relapsed or Refractory Follicular Lymphoma</u></p><p>&nbsp;</p><p>The safety of Yescarta was evaluated in ZUMA-5, a study that included 146 patients with relapsed or refractory iNHL (124 patients with FL and 22 with marginal zone lymphoma) who received CD19-positive CAR T cells (see section 5.1). Patients with a history of CNS disorders or autoimmune disease requiring systemic immunosuppression were ineligible. The median age was 61 years (range: 34 to 79 years), 43% were female, 93% were white, 3% were black, and 1% were Asian.</p><p>&nbsp;</p><p>The most common non-laboratory adverse reactions (incidence &ge; 20%) included fever, CRS, hypotension, encephalopathy, fatigue, headache, infections with pathogen unspecified, tachycardia, febrile neutropenia, musculoskeletal pain, nausea, tremor, chills, diarrhea, constipation, decreased appetite, cough, vomiting, hypoxia, arrhythmia, and dizziness. Serious adverse reactions occurred in 48% of patients. Serious adverse reactions in &gt; 2% of patients included febrile neutropenia, encephalopathy, fever, CRS, infections with pathogen unspecified, pneumonia, hypoxia, and hypotension.</p><p>&nbsp;</p><p>The most common (&ge; 10%) Grade 3 or higher reactions included febrile neutropenia, encephalopathy, and infections with pathogen unspecified. Fatal adverse reactions occurred in 1% of patients and included CRS and fungal infection.</p><p>&nbsp;</p><p>Fifty-one percent (75/146) of patients received tocilizumab after infusion of Yescarta.</p><p>&nbsp;</p><p>Table 7 summarizes the adverse reactions, excluding laboratory terms, that occurred in at least 10% of patients treated with Yescarta and Table&nbsp;8 describes Grade 3 or 4 laboratory abnormalities that developed or worsened in at least 10% of patients.</p><p><strong>Table </strong><strong>7.</strong>&nbsp;&nbsp;&nbsp; <strong>Adverse Reactions in &ge; 10% of Patients Treated with Yescarta in ZUMA-5 (N = 146)</strong></p><table border="0" cellspacing="0" cellpadding="0" summary="Table 5. Summary of Adverse Reactions Observed in at Least 10% of Patients Treated with Yescarta in ZUMA-5 (N=146)
Blood and Lymphatic System Disorders  
Adverse Reaction. Febrile neutropenia. Refer to footnote a. Any Grade: 41%. Grade 3 or Higher: 41%.                                             
                                                                                                                      Cardiac Disorders  
Adverse Reaction. Tachycardias Refer to footnote b. Any Grade: 44%. Grade 3 or Higher: 1%.
Adverse Reaction. Arrhythmias Refer to footnote c. Any Grade: 21%. Grade 3 or Higher: 2%.

Gastrointestinal Disorders  
Adverse Reaction. Nausea. Any Grade: 40%. Grade 3 or Higher: 0%         Adverse Reaction. Diarrhea. Refer to footnote d. Any Grade: 29%. Grade 3 or Higher: 1%.                                                                                                       Adverse Reaction. Constipation. Any Grade: 28%. Grade 3 or Higher: 0%. Adverse Reaction. Vomiting. Any Grade: 24%. Grade 3 or Higher: 1%. 
Adverse Reaction. Abdominal pain Refer to footnote e. Any Grade: 16%. Grade 3 or Higher: 0%.

General Disorders and Administration Site Conditions  
Adverse Reaction. Fever. Any Grade: 85%. Grade 3 or Higher: 8%.
Adverse Reaction. Fatigue Refer to footnote f. Any Grade: 49%. Grade 3 or Higher: 1%.
Adverse Reaction. Chills. Any Grade: 29%. Grade 3 or Higher: 0%.
Adverse Reaction. Edema Refer to footnote g. Any Grade: 13%. Grade 3 or Higher: 1%.
                                                                                                                                                                                                                                                                                                                                  Immune System Disorders  
Adverse Reaction. Cytokine release syndrome. Any Grade: 84%. Grade 3 or Higher: 8%.
Adverse Reaction. Immunoglobulins decreased. Refer to footnote h. Any Grade: 18%. Grade 3 or Higher: 1%.

Infections and Infestations  
Adverse Reaction. Infection with pathogen unspecified. Any Grade: 45%. Grade 3 or Higher: 14%. 
Adverse Reaction. Pneumonia. Refer to footnote i. Any Grade: 13%. Grade 3 or Higher: 8%.
Adverse Reaction. Fungal infections. Any Grade: 12%. Grade 3 or Higher: 2%.
Adverse Reaction. Virual infections. Any Grade: 13%. Grade 3 or Higher: 2%.
                                                                                                                            Metabolism and Nutrition Disorder                                                                       Adverse Reaction. Decreased appetite. Refer to footnote j. Any Grade: 26%. Grade 3 or Higher: 1%.                                                                                  Musculoskeletal and Connective Tissue Disorders  
Adverse Reaction. Musculoskeletal pain. Refer to footnote k. Any Grade: 40%. Grade 3 or Higher: 1%.                  
Adverse Reaction. Motor dysfunction. Refer to footnote m. Any Grade: 18%. Grade 3 or Higher: 2%.
                                                                                                                          Nervous System Disorders  
Adverse Reaction. Encephalopathy Refer to footnote m. Any Grade: 49%. Grade 3 or Higher: 16%. 
Adverse Reaction. Headache. Any Grade: 45%. Grade 3 or Higher: 1%.
Adverse Reaction. Tremor. Any Grade: 31%. Grade 3 or Higher: 1%.        Adverse Reaction. Dizziness Refer to footnote n.  Any Grade: 20%. Grade 3 or Higher: 0%.                                                                                                       Adverse Reaction. Aphasia. Any Grade: 14%. Grade 3 or Higher: 4%. 
Adverse Reaction. Neuropathy peripheral. Refer to footnote o. Any Grade: 12%. Grade 3 or Higher: 0%. 
Adverse Reaction. Ataxia. Refer to footnote p. Any Grade: 10%. Grade 3 or Higher: 4%.                                                                                                                                                                                                                                                                                                                                                                          Psychiatric Disorders  
Adverse Reaction. Delirium Refer to footnote q. Any Grade:16%. Grade 3 or Higher: 5%.                                                                                                                       
Adverse Reaction. Insomnia.  Any Grade:16%. Grade 3 or Higher: 0%.                                                                                                                Adverse Reaction. Affective disorder. Refer to footnote r. Any Grade:10%. Grade 3 or Higher: 1%.                                                                                                                Respiratory, Thoracic and Mediastinal Disorders  
Adverse Reaction. Cough Refer to footnote s. Any Grade: 25%. Grade 3 or Higher: 0%.                                                                                                       Adverse Reaction. Hypoxia. Any Grade: 23%. Grade 3 or Higher: 8%. 
Adverse Reaction. Dyspnea Refer to footnote t. Any Grade: 12%. Grade 3 or Higher: 1%. 
Adverse Reaction. Nasal congestion. Any Grade: 10%. Grade 3 or Higher: 0%. 

Skin and Subcutaneous Tissue Disorders
Adverse Reaction. Rash. Refer to footnote u. Any Grade: 19%. Grade 3 or Higher: 3%. 
 
Vascular Disorders  
Adverse Reaction. Hypotension Refer to footnote v. Any Grade: 51%. Grade 3 or Higher: 4%. 
Adverse Reaction. Hypertension. Any Grade: 13%. Grade 3 or Higher: 6%.
Adverse Reaction. Thrombosis Refer to footnote w. Any Grade: 12%. Grade 3 or Higher: 4%.                                                                                                                                                                                                             Footnotes:
                                                                                                                                a. Febrile neutropenia includes febrile neutropenia, fever overlapping with neutropenia.
b. Tachycardia includes tachycardia, sinus tachycardia.
c. Arrhythmia includes atrial fibrillation, atrioventricular block first degree, bradycardia, sinus bradycardia, supraventricular tachycardia, ventricular arrhythmia, ventricular extrasystoles, ventricular tachycardia, electrocardiogram QT prolonged, electrocardiogram T wave inversion.
d. Diarrhea includes diarrhea, colitis, enteritis
e. Abdominal pain includes abdominal pain, abdominal discomfort, abdominal pain lower, abdominal pain upper, abdominal tenderness, dyspepsia, epigastric discomfort.
f. Fatigue includes asthenia, fatigue, decreased activity, malaise.
g. Edema includes edema, face edema, generalized edema, localized edema, edema peripheral, peripheral swelling, pulmonary edema, swelling face.
h. Immunoglobulins decreased includes hypogammaglobulinemia, blood immunoglobulin G decreased.
i. Pneumonia includes pneumonia streptococcal, pneumonia, lung infiltration. Pneumonia is also summarized under infections with pathogen unspecified.
j. Decreased appetite includes decreased appetite, hypophagia.
k. Musculoskeletal pain includes musculoskeletal pain, arthralgia, back pain, bone pain, flank pain, groin pain, musculoskeletal chest pain, myalgia, neck pain, osteoarthritis, pain in extremity.
l. Motor dysfunction includes motor dysfunction, muscle rigidity, muscle spasms, muscle strain, muscular weakness.
m. Encephalopathy includes agraphia, amnesia, aphonia, apraxia, CAR T-cell-related encephalopathy syndrome, cognitive disorder, disturbance in attention, dysarthria, dysgraphia, dyskinesia, encephalopathy, lethargy, loss of consciousness, memory impairment, somnolence, speech disorder, confusional state, mental status changes, immune effector cell-associated neurotoxicity, neurotoxicity, toxic encephalopathy.
n. Dizziness includes dizziness, presyncope, syncope, vertigo.
o. Neuropathy peripheral includes allodynia, cervical radiculopathy, hyperesthesia, hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy.
p. Ataxia includes ataxia, balance disorder, gait disturbance, vestibular disorder.
q. Delirium includes agitation, delirium, hallucination, restlessness.
r. Affective disorder includes anxiety, depression, impulsive behavior, mania, panic attack.
s. Cough includes cough, productive cough, upper-airway cough syndrome.
t. Dyspnea includes dyspnea, dyspnea exertional.
u. Rash includes dermatitis bullous, erythema, pruritus, rash, rash macular, rash maculo-papular, Stevens-Johnson syndrome, urticaria.
v. Hypotension includes capillary leak syndrome, hypotension, hypoperfusion, orthostatic hypotension.
w. Thrombosis includes deep vein thrombosis, embolism, peripheral ischemia, pulmonary embolism, thrombosis in device, vascular occlusion, jugular vein thrombosis
                                                                                                                " style="width:606px"><thead><tr><td style="vertical-align:bottom"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:bottom"><p><strong>Any Grade (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>Grade 3 or Higher (%)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em><em> </em></p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia <sup>a</sup></p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>41</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Cardiac Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia <sup>b</sup></p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia <sup>c</sup></p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Gastrointestinal Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea <sup>d</sup></p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain <sup>e</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>General Disorders and Administration Site Conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>85</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue <sup>f</sup></p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Edema <sup>g</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Immune System Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Cytokine release syndrome</p></td><td style="vertical-align:top"><p>84</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Immunoglobulins decreased <sup>h</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Infections and Infestations</em></p></td></tr><tr><td style="vertical-align:top"><p>Infections with pathogen unspecified</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>14</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia <sup>i</sup></p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Fungal infections</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Viral Infections</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Metabolism and Nutrition Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite <sup>j</sup></p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Musculoskeletal and Connective Tissue Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain <sup>k</sup></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Motor dysfunction <sup>l</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Nervous System Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Encephalopathy <sup>m</sup></p></td><td style="vertical-align:top"><p>49</p></td><td style="vertical-align:top"><p>16</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Tremor</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness <sup>n</sup></p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Aphasia</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Neuropathy peripheral <sup>o</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Ataxia <sup>p</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Psychiatric Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Delirium <sup>q</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Affective disorder <sup>r</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Respiratory, Thoracic and Mediastinal Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Cough <sup>s</sup></p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hypoxia</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea <sup>t</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Nasal congestion&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Skin and Subcutaneous Tissue Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Rash <sup>u</sup></p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Vascular Disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension <sup>v</sup></p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Thrombosis <sup>w</sup></p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Febrile neutropenia includes febrile neutropenia, fever overlapping with neutropenia.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia includes tachycardia, sinus tachycardia.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arrhythmia includes atrial fibrillation, atrioventricular block first degree, bradycardia, sinus bradycardia, supraventricular tachycardia, ventricular arrhythmia, ventricular extra systoles, ventricular tachycardia, electrocardiogram QT prolonged, electrocardiogram T wave inversion.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea&nbsp;includes&nbsp;diarrhea,&nbsp;colitis, enteritis.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain includes abdominal pain, abdominal discomfort, abdominal pain lower, abdominal pain upper, abdominal tenderness, dyspepsia, epigastric discomfort.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue includes asthenia, fatigue, decreased activity, malaise.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Edema includes edema, face edema, generalized edema, localized edema, edema peripheral, peripheral swelling, pulmonary edema, swelling face.</p><p>h.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immunoglobulins decreased includes hypogammaglobulinemia, blood immunoglobulin G decreased.</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia includes pneumonia streptococcal, pneumonia, lung infiltration. Pneumonia is also summarized under infections with pathogen unspecified.</p><p>j.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite includes decreased appetite, hypophagia.</p><p>k.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal pain includes musculoskeletal pain, arthralgia, back pain, bone pain, flank pain, groin pain, musculoskeletal chest pain, myalgia, neck pain, osteoarthritis, pain in extremity.</p><p>l.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Motor dysfunction includes motor dysfunction, muscle rigidity, muscle spasms, muscle strain, muscular weakness.</p><p>m.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy includes agraphia, amnesia, aphonia, apraxia, CAR T-cell-related encephalopathy syndrome, cognitive disorder, disturbance in attention, dysarthria, dysgraphia, dyskinesia, encephalopathy, lethargy, loss of consciousness, memory impairment, somnolence, speech disorder, confusional state, mental status changes, immune effector cell-associated neurotoxicity, neurotoxicity, toxic encephalopathy.</p><p>n.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness includes dizziness, presyncope, syncope, vertigo.</p><p>o.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuropathy peripheral includes allodynia, cervical radiculopathy, hyperesthesia, hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy.</p><p>p.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ataxia includes ataxia, balance disorder, gait disturbance, vestibular disorder.</p><p>q.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Delirium includes agitation, delirium, hallucination, restlessness.</p><p>r.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Affective disorder includes anxiety, depression, impulsive behavior, mania, panic attack.</p><p>s.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough includes cough, productive cough, upper-airway cough syndrome.</p><p>t.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnea includes dyspnea, dyspnea exertional.</p><p>u.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash includes dermatitis bullous, erythema, pruritus, rash, rash macular, rash maculo-papular, Stevens-Johnson syndrome, urticaria.</p><p>v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension includes capillary leak syndrome, hypotension, hypoperfusion, orthostatic hypotension.</p><p>w.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombosis includes deep vein thrombosis, embolism, peripheral ischemia, pulmonary embolism, thrombosis in device, vascular occlusion, jugular vein thrombosis.</p></td></tr></tbody></table><p>&nbsp;</p><p>Other clinically important adverse reactions that occurred in less than 10% of patients treated with Yescarta include the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Blood and lymphatic system disorders:</em> Coagulopathy (6%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Cardiac disorders:</em> Cardiac failure (2%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Eye disorders: </em>Visual impairment (5%), blindness (1%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Gastrointestinal disorders: </em>Dysphagia (6%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>General disorders and administration site conditions: </em>Multiple organ dysfunction syndrome (1%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Infections and infestations:</em> Bacterial infections (8%), sepsis (2%), herpesvirus infection (4%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Musculoskeletal and connective tissue disorders:</em> Muscle injury (1%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Nervous system disorders:</em> Seizure (2%), hemiparesis (2%), ischemic stroke (1%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Renal and urinary disorders:</em> Renal insufficiency (8%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Respiratory, thoracic and mediastinal disorders:</em> Respiratory failure (1%)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Vascular disorders: </em>Hemorrhage (8%)</p><p>&nbsp;</p><p>Laboratory abnormalities:</p><p>&nbsp;</p><p>Table 8.&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 or 4 Laboratory Abnormalities Occurring in &ge; 10% of Patients in ZUMA-5 Following Treatment with <em>Yescarta</em><sup>1</sup><sup> </sup>(N = 146)</p><table border="1" cellspacing="0" cellpadding="0" summary="Table 6. Grade 3 or 4 Laboratory Abnormalities Occurring in ≥ 10% of Patients in ZUMA-5 Following Treatment with YESCARTA (N = 146). 
                                                                                                                          Neutropenia. Grades 3 or 4: 92%                                                                 Leukopenia. Grades 3 or 4: 92%                                                      Thrombocytopenia. Grades 3 or 4: 35%                                                          
Anemia. Grades 3 or 4: 30%
Hypophosphatemia. Grades 3 or 4: 25%
Lymphopenia. Grades 3 or 4: 23% 
Hyponatremia. Grades 3 or 4: 10% 
Hyperglycemia. Grade 3 or 4: 10%
Hyperuricemia. Grades 3 or 4: 10%
Hypocalcemia. Grades 3 or 4: 10%
" style="width:413px"><tbody><tr><td><p><strong>Laboratory Abnormality</strong></p></td><td style="vertical-align:bottom"><p><strong>Grades 3 or 4 (%)</strong></p></td></tr><tr><td><p>Lymphocyte decrease</p></td><td><p>96</p></td></tr><tr><td><p>Leukocyte decrease</p></td><td><p>94</p></td></tr><tr><td><p>Neutrophil decrease</p></td><td><p>92</p></td></tr><tr><td><p>Platelet decrease</p></td><td><p>35</p></td></tr><tr><td><p>Hemoglobin decrease</p></td><td><p>32</p></td></tr><tr><td><p>Phosphate decrease</p></td><td><p>25</p></td></tr><tr><td><p>Sodium decrease</p></td><td><p>10</p></td></tr><tr><td><p>Glucose increase</p></td><td><p>10</p></td></tr><tr><td><p>Calcium decrease</p></td><td><p>10</p></td></tr></tbody></table><p><sup>1</sup>Baseline lab values were assessed prior to lymphodepleting chemotherapy.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Immunogenicity </u></p><p>Yescarta has the potential to induce anti-product antibodies. The immunogenicity of Yescarta has been evaluated using an enzyme-linked immunosorbent assay (ELISA) for the detection of binding antibodies against FMC63, the originating antibody of the anti-CD19 CAR. Eleven patients (4%) tested positive for pre-dose anti-FMC63 antibodies at baseline in ZUMA-7 and ZUMA-1, and one patient (1%) who had a negative test result at baseline had a positive test result post administration of Yescarta in the screening ELISA in ZUMA-7. In ZUMA-5, 19 patients (13%) were antibody-positive at baseline, and 3 patients (2%) who had negative test results at baseline had positive test results post administration of Yescarta in the screening ELISA. Results of a confirmatory cell-based assay, leveraging a properly folded and expressed extracellular portion of the CAR (ScFv, hinge and linker) demonstrated that all patients treated with Yescarta that had a positive result in the screening ELISA were antibody negative at all time points tested. There is no evidence that the kinetics of initial expansion and persistence of Yescarta, or the safety or effectiveness of Yescarta, was altered in these patients.</p><p>&nbsp;</p><p><u>Post-marketing Experience</u></p><p>The following adverse reactions have been identified during post-approval use of Yescarta. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&nbsp;</p><p><em>Nervous System Disorders</em></p><p>Spinal cord edema, myelitis, quadriplegia, dysphagia, and status epilepticus.</p><p>Immune System Disorders</p><p>Infusion related reactions</p><p>&nbsp;</p><p><u>To reports any side effect(s):</u></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&middot; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data regarding the signs of overdose with Yescarta.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacotherapeutic group:</u> Other antineoplastic agents, ATC code: L01XL03</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Yescarta, a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19‑expressing cancer cells and normal B cells. Studies demonstrated that following anti-CD19 CAR T cell engagement with CD19‑expressing target cells, the CD28 and CD3-zeta co-stimulatory domains activate downstream signaling cascades that lead to T cell activation, proliferation, acquisition of effector functions and secretion of inflammatory cytokines and chemokines. This sequence of events leads to killing of CD19-expressing cells.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects </u></p><p>&nbsp;</p><p>After Yescarta infusion, pharmacodynamic responses were evaluated over a 4-week interval by measuring transient elevation of cytokines, chemokines and other molecules in blood. Levels of cytokines and chemokines such as IL-6, IL-8, IL-10, IL-15, TNF-&alpha;, IFN-&gamma;, and sIL2R&alpha; were analyzed. Peak elevation was observed within the first 14 days after infusion, and levels generally returned to baseline within 28 days.</p><p>&nbsp;</p><p>Due to the on-target effect of Yescarta, a period of B-cell aplasia is expected.</p><p>&nbsp;</p><p><em>Large B-cell lymphoma</em></p><p>Among patients with LBCL with an ongoing response at 24 months in the ZUMA-7 study, 21 of 61 evaluable patients (34%) had no detectable B cells at baseline, and the majority of patients at Month 3 (43 of 69 evaluable patients [62%]) and Month 6 (8 of 13 evaluable patients [62%]) had no detectable B cells. At Month 24, 20 of 24 evaluable patients (83%) had detectable B cells.</p><p>&nbsp;</p><p>Among patients with LBCL with an ongoing response at 24 months in the ZUMA-1 study, 13 of 29 evaluable patients (45%) had no detectable B cells at baseline, and the majority of patients at Month 3 (28 of 35 evaluable patients [80%]) and Month 6 (25 of 32 evaluable patients [78%]) had no detectable B cells. At Month 24, 24 of 32 evaluable patients (75%) had detectable B cells.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Relapsed or Refractory Large B-Cell Lymphoma</em></p><p><em>&nbsp;</em></p><p><em>ZUMA-7</em></p><p>A randomized, open-label, multicenter trial evaluated the efficacy of Yescarta in adult patients with relapsed or refractory LBCL after first-line chemoimmunotherapy that included rituximab and anthracycline (ZUMA-7; NCT03391466). Patients had not yet received treatment for relapsed or refractory lymphoma and were potential candidates for autologous HSCT. Patients were required to have primary refractory disease or relapse within 12 months following completion of first-line therapy. The study excluded patients with primary mediastinal B-cell lymphoma, any history of central nervous system lymphoma, need for urgent therapy due to tumor mass effect, active or serious infections, and ECOG performance status of 2 or greater.</p><p>&nbsp;</p><p>In total, 359 patients were randomized in a 1:1 ratio to receive a single infusion of Yescarta or to receive second-line standard therapy, consisting of 2 or 3 cycles of chemoimmunotherapy followed by high-dose therapy and autologous HSCT in patients who attained CR or PR. Randomization was stratified by response to first-line therapy and second-line age-adjusted International Prognostic Index.</p><p>&nbsp;</p><p>Following lymphodepleting chemotherapy, Yescarta was administered as a single intravenous infusion at a target dose of 2 &times; 10<sup>6</sup> CAR-positive viable T cells/kg (maximum permitted dose: 2 &times; 10<sup>8</sup> cells). The lymphodepleting regimen consisted of cyclophosphamide 500 mg/m<sup>2</sup> intravenously and fludarabine 30 mg/m<sup>2</sup> intravenously, both given on the fifth, fourth, and third day before Yescarta. All patients who received Yescarta were monitored at a healthcare facility for a minimum of 7 days. Bridging therapy, administered between leukapheresis and lymphodepleting chemotherapy, was limited to corticosteroids and was permitted for patients with high disease burden.</p><p>&nbsp;</p><p>In the overall study population, the median age was 59 years (range: 21 to 81 years), 66% were male, 83% were white, 6% were Asian, and 5% were Black. The diagnoses included de novo DLBCL NOS (63%), HGBL with or without <em>MYC</em> and <em>BCL-2</em> and/or <em>BCL-6</em> rearrangements (19%), and large cell transformation of follicular lymphoma (13%). In total, 74% of patients had primary refractory LBCL, and 26% had relapsed disease within 12 months of first-line therapy.</p><p>&nbsp;</p><p>Of the 180 patients randomized to receive Yescarta, 178 underwent leukapheresis and 170 were treated with Yescarta, of whom 60 (33%) received bridging corticosteroid therapy. Eight patients (4%) were not treated following leukapheresis, primarily due to progressive disease, serious adverse events, or death. The median time from leukapheresis to product delivery was 18 days (range: 13 to 49 days), and from leukapheresis to Yescarta infusion was 26 days (range: 16 to 52 days). The median dose was 2.0 &times; 10<sup>6</sup> CAR-positive viable T cells/kg (range: 1.0 to 2.1 &times; 10<sup>6</sup> cells/kg).</p><p>&nbsp;</p><p>Of the 179 patients randomized to receive standard therapy, 168 patients received any study treatment, and 62 (35%) received high-dose therapy and on-protocol HSCT. The most common reason for not receiving HSCT was lack of response to salvage chemotherapy.</p><p>&nbsp;</p><p>The primary efficacy measure was event-free survival (EFS) as determined by an independent review committee. &nbsp;Efficacy is summarized in Table 9 and Figure 1. With an estimated median follow-up of 22.1 months overall, the estimated EFS rate at 18 months was 41.5% [95% CI: 34.2, 48.6] in the Yescarta arm and 17.0% [95% CI: 11.8, 23.0] in the standard therapy arm.</p><p>&nbsp;</p><p>In the Yescarta arm, the estimated median DOR was 28.4 months (95% CI: 26.9, NE) in patients who achieved CR and 1.6 months (95% CI: 1.4, 1.9) in patients who achieved a best response of PR.</p><p>&nbsp;</p><p>At the time of the primary EFS analysis, the interim analysis of overall survival (OS) did not meet criteria for statistical significance.</p><p>With an estimated median follow-up of 46.7 months overall, the primary analysis of OS showed a statistically significant improvement in the Yescarta arm compared to the standard therapy arm. Fifty-seven percent of patients received cellular immunotherapy after no response to or relapse after randomization to standard therapy arm.</p><p>&nbsp;</p><p>The efficacy results are summarized on Table 9 and Figure 1 and Figure 2.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy Results for ZUMA-7</p><table border="1" cellspacing="0" cellpadding="0" summary="Table 9 Efficacy Results for ZUMA-7. Yescarta (n=180); Standard Therapy (n=179). 

Event Free survival: 
Number of events, n(%): 108 (6) for Yescarta; 144(80) for Standard Therapy.
 Median, months [95% CI]c : 8.3 [4.5, 15.8] for Yescarta; 2.0 (1.6, 2.8) for Standard Therapy
Stratified hazard ratio [95% CI]: 0.4 [0.31, 0.51]
 Stratified log-rank p-value &lt;0.0001

Best Objective Response Rate, % [95% CI] 83 [77, 88] for Yescarta; 50 [43, 58] for Standard Therapy
   Difference in ORR, % [95% CI] 33 [23, 42]
   Stratified p-valued &lt;0.0001
   Complete remission rate, % [95% CI] 65 [58, 72] for Yescarta; 32 [26, 40] for Standard Therapy
 Partial remission rate, % [95% CI] 18 [13, 25] for Yescarta; 18 [13, 24] for Standard Therapy
Progression-Free Survival  
   Number of events, n (%)  93 (52) for Yescarta; 81 (45) for Standard Therapy
   Median, months [95% CI] c  14.9 [7.2, NE] for Yescarta;  5.0 [3.4, 8.5] for Standard Therapy
   Stratified hazard ratio [95% CI]  0.56 [0.41, 0.76]
" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Outcome<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Yescarta &nbsp;</strong></p><p><strong>(N = 180)<sup>g</sup></strong></p></td><td style="vertical-align:top"><p><strong>Standard Therapy</strong></p><p><strong>(N = 179)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Event-Free Survival<sup>b</sup></strong></p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Number of events, n (%)</p></td><td><p>108 (60)</p></td><td style="vertical-align:top"><p>144 (80)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Median, months [95% CI]<sup>c</sup></p></td><td><p>8.3 [4.5, 15.8]</p></td><td style="vertical-align:top"><p>2.0 [1.6, 2.8]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Stratified hazard ratio [95% CI]</p></td><td colspan="2"><p>0.40 [0.31, 0.51]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Stratified log-rank p-value</p></td><td colspan="2"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Survival<sup>d</sup></strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Number of events, n (%)</p></td><td><p>82 (46)</p></td><td><p>95 (53)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Median OS, months [95% CI]<sup>c</sup></p></td><td><p>NE (28.6, NE)</p></td><td><p>31.1 (17.1, NE)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Stratified hazard ratio [95% CI]</p></td><td colspan="2"><p>0.73 (0.54, 0.98)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Stratified log-rank p-value<sup>e</sup></p></td><td colspan="2"><p>0.0168</p></td></tr><tr><td style="vertical-align:top"><p><strong>Best Objective Response Rate, % [95% CI]</strong></p></td><td><p>83 [77, 88]</p></td><td style="vertical-align:top"><p>50 [43, 58]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Difference in ORR, % [95% CI]</p></td><td colspan="2"><p>33 [23, 42]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Stratified p-value<sup>f</sup></p></td><td colspan="2"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Complete remission rate, % [95% CI]</p></td><td><p>65 [58, 72]</p></td><td style="vertical-align:top"><p>32 [26, 40]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Partial remission rate, % [95% CI]</p></td><td><p>18 [13, 25]</p></td><td style="vertical-align:top"><p>18 [13, 24]</p></td></tr><tr><td style="vertical-align:top"><p><strong>Progression-Free Survival</strong></p></td><td><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Number of events, n (%)</p></td><td><p>&nbsp;93 (52)</p></td><td style="vertical-align:top"><p>&nbsp;81 (45)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Median, months [95% CI]<sup> c</sup></p></td><td><p>&nbsp;14.9 [7.2, NE]</p></td><td style="vertical-align:top"><p>&nbsp;5.0 [3.4, 8.5]</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp;Stratified hazard ratio [95% CI]</p></td><td colspan="2"><p>&nbsp;0.56 [0.41, 0.76]</p></td></tr></tbody></table><p>CI, confidence interval; NE, not estimable.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Per the International Working Group Lugano Classification (Cheson 2014), as assessed by the independent review committee.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EFS is defined as time from randomization to the earliest date of disease progression or relapse, best response of stable disease up to and including the Day 150 assessment, commencement of new lymphoma therapy, or death from any cause.&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier estimate.&nbsp;</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overall survival was conducted at the time of the primary OS analysis</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p-value is compared with 0.0249, the one-sided efficacy boundary (significance level) for the primary OS analysis.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Per Cochran-Mantel-Haenszel method.&nbsp; For all stratified analyses, stratification was based on response to first-line therapy (primary refractory, vs relapse within 6 months of first-line therapy vs relapse within &gt; 6 but &le; 12 months) and second-line age-adjusted International Prognostic Index.</p><p>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two recipients of non-conformal product are included in the efficacy analysis.</p><p>&nbsp;</p><p>Figure <!--[if supportFields]><span
style='mso-bookmark:_Ref476420547'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Ref476420547'><span lang=EN-GB style='font-size:11.0pt'><span
style='mso-spacerun:yes'> </span>SEQ Figure \* ARABIC </span></span><span
style='mso-bookmark:_Ref476420547'><i><span lang=EN-GB style='font-size:11.0pt;
font-weight:normal'><span style='mso-element:field-separator'></span></span></i></span><![endif]-->1<!--[if supportFields]><span
style='mso-bookmark:_Ref476420547'></span><span style='mso-element:field-end'></span><![endif]-->. Kaplan-Meier Curve of Event-Free Survival in ZUMA-7 (Primary EFS Analysis)</p><p>&nbsp;</p><p><em>&nbsp;<img src="data:image/png;base64,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" alt="" width="605" height="329" vspace="0" hspace="0" border="0" style="width:605px;height:329px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></em></p><p><em>&nbsp;</em></p><p><br />Figure 2. Kaplan-Meier Curve of Overall Survival in ZUMA-7 (Primary OS Analysis)</p><p><em>&nbsp;</em></p><p><img src="data:image/png;base64,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" alt="" width="605" height="351" vspace="0" hspace="0" border="0" style="width:605px;height:351px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><em>&nbsp;</em></p><p><em>ZUMA-1</em></p><p>A single-arm, open-label, multicenter trial evaluated the efficacy of a single infusion of Yescarta in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (ZUMA-1; NCT02348216). Eligible patients had refractory disease to the most recent therapy or relapse within 1 year after autologous HSCT. The study excluded patients with prior allogeneic HSCT, any history of central nervous system lymphoma, ECOG performance status of 2 or greater, absolute lymphocyte count less than 100/&micro;L, creatinine clearance less than 60 mL/min, hepatic transaminases more than 2.5 times the upper limit of normal, cardiac ejection fraction less than 50%, or active serious infection.</p><p>&nbsp;</p><p>Following lymphodepleting chemotherapy, Yescarta was administered as a single intravenous infusion at a target dose of 2 &times; 10<sup>6</sup> CAR-positive viable T cells/kg (maximum permitted dose: 2 &times; 10<sup>8</sup> cells). The lymphodepleting regimen consisted of cyclophosphamide 500&nbsp;mg/m<sup>2</sup> intravenously and fludarabine 30&nbsp;mg/m<sup>2</sup> intravenously, both given on&nbsp;the fifth, fourth, and third day before Yescarta. Bridging chemotherapy between leukapheresis and lymphodepleting chemotherapy was not permitted. All patients were hospitalized for Yescarta infusion and for a minimum of 7 days afterward.</p><p>&nbsp;</p><p>Of 111 patients who underwent leukapheresis, 101 received Yescarta. Of the patients treated, the median age was 58 years (range: 23 to 76 years), 67% were male, and 89% were white. Most (76%) had DLBCL, 16% had transformed follicular lymphoma, and 8% had primary mediastinal large B-cell lymphoma. The median number of prior therapies was 3 (range: 1 to 10), 77% of the patients had refractory disease to a second or greater line of therapy, and 21% had relapsed within 1 year of autologous HSCT.</p><p>&nbsp;</p><p>One out of 111 patients did not receive the product due to manufacturing failure. Nine other patients were not treated, primarily due to progressive disease or serious adverse reactions following leukapheresis. The median time from leukapheresis to product delivery was 17 days (range: 14 to 51 days), and the median time from leukapheresis to infusion was 24 days (range: 16 to 73 days). The median dose was 2.0 &times; 10<sup>6 </sup>CAR-positive viable T cells/kg (range: 1.1 to 2.2 &times; 10<sup>6</sup> cells/kg).</p><p>&nbsp;</p><p>Efficacy was established on the basis of complete remission (CR) rate and duration of response (DOR), as determined by an independent review committee (Table 10 and Table 11). The median time to response was 0.9 months (range: 0.8 to 6.2 months). Response durations were longer in patients who achieved CR, as compared to patients with a best response of partial remission (PR) (Table 11). Of the 52 patients who achieved CR, 14 initially had stable disease (7 patients) or PR (7 patients), with a median time to improvement of 2.1 months (range: 1.6 to 5.3 months).</p><p>&nbsp;</p><p><strong>Table </strong><strong>10.</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Response Rate in Patients with Relapsed or Refractory LBCL in ZUMA-1</strong></p><table border="0" cellspacing="0" cellpadding="0" summary="Table 7. Response Rate in Patients with Relapsed or Refractory LBCL
                                                                                                                   Recipients of YESCARTA (N=101)
Objective Response Rate Refer to footnote a, n=73 (72%), 95% CI: (62, 81)
Complete Remission Rate, n=52 (51%), 95% CI: (41, 62)
Partial Remission Rate, n =21 (21%), 95% CI: (13, 30)                               Footnote:                                                                                                              CI, confidence interval.
a. Per 2007 revised International Working Group criteria, as assessed by the independent review committee.

" style="width:98%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>Recipients of Yescarta</strong></p><p><strong>(N = 101)</strong></p></td></tr><tr><td><p><strong>Objective Response Rate</strong><sup>a</sup></p></td><td><p>73 (72%)</p></td></tr><tr><td><p>(95% CI)</p></td><td><p>(62, 81)</p></td></tr><tr><td><p>Complete Remission Rate</p></td><td><p>52 (51%)</p></td></tr><tr><td><p>(95% CI)</p></td><td><p>(41, 62)</p></td></tr><tr><td><p>Partial Remission Rate</p></td><td><p>21 (21%)</p></td></tr><tr><td><p>(95% CI)</p></td><td><p>(13, 30)</p></td></tr></tbody></table><p>CI, confidence interval.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Per 2007 revised International Working Group criteria, as assessed by the independent review committee.</p><p>&nbsp;</p><p><strong>Table 11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Duration of Response</strong><strong> in Patients with Relapsed or Refractory LBCL in ZUMA-1</strong></p><table border="0" cellspacing="0" cellpadding="0" summary="Table 8. Duration of Response in Patients with Relapsed or Refractory LBCL From N of 101                                                                                           Number of Responders 73.                                                                                 Number of Responders. DOR (Months). Refer to footnote a.
DOR. Median in months: Refer to footnote b. 9.2, (95% CI) (5.4, NE)       DOR. Range. Refer to footnote c.  0.03+, 14.4+
DOR. if Best Response is CR (Months).                                                        DOR. Median in months. Refer to footnote b. NE, (95% CI) (8.1, NE)       DOR. Range in months. Refer to footnote c.  0.4+, 14.4+
DOR if best response is PR (Months)                                                           DOR. Median in months. Refer to footnote b. 2.1, (95% CI) (1.3, 5.3)              DOR. Range in months. Refer to footnote c. 0.03+, 8.4+
Median Follow-up for DOR (Months). Refer to footnote a and b. 7.9                                                                    Footnotes:
CR, complete remission; DOR, duration of response; NE, not estimable; PR, partial remission. 
a. Among all responders. DOR is measured from the date of first objective response to the date of progression or death from relapse or toxicity.  
b. Kaplan-Meier estimate. 
c. A “+” sign indicates a censored value.
" style="width:98%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>From N of 101</strong></p></td></tr><tr><td><p><strong>Number of Responders</strong></p></td><td><p>73</p></td></tr><tr><td><p><strong>DOR (Months)</strong><sup>a<strong> </strong></sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>b</sup></p></td><td><p>9.2</p></td></tr><tr><td><p>(95% CI)</p></td><td><p>(5.4, NE)</p></td></tr><tr><td><p>Range<sup>c</sup></p></td><td><p>0.03+, 14.4+</p></td></tr><tr><td><p><strong>DOR if Best Response is CR (Months)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>b</sup></p></td><td><p>NE</p></td></tr><tr><td><p>(95% CI)</p></td><td><p>(8.1, NE)</p></td></tr><tr><td><p>Range<sup>c</sup><sup> </sup></p></td><td><p>0.4, 14.4+</p></td></tr><tr><td><p><strong>DOR if Best Response is PR (Months)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>b</sup></p></td><td><p>2.1</p></td></tr><tr><td><p>(95% CI)</p></td><td><p>(1.3, 5.3)</p></td></tr><tr><td><p>Range<sup>c</sup></p></td><td><p>0.03+, 8.4+</p></td></tr><tr><td><p><strong>Median Follow-up for DOR (Months)</strong><sup>a, b</sup></p></td><td><p>7.9</p></td></tr></tbody></table><p>CR, complete remission; DOR, duration of response; NE, not estimable; PR, partial remission.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Among all responders. DOR is measured from the date of first objective response to the date of progression or death from relapse or toxicity.&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier estimate.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A &ldquo;+&rdquo; sign indicates a censored value.</p><p>&nbsp;</p><p>Relapsed or Refractory Follicular Lymphoma</p><p>Efficacy in FL is based on a single-arm, open-label, multicenter trial (ZUMA-5; NCT03105336) that evaluated a single infusion of Yescarta in adult patients with relapsed or refractory FL after two or more lines of systemic therapy, including the combination of an anti-CD20 monoclonal antibody and an alkylating agent. The study excluded patients with active or serious infections, transformed lymphoma or other aggressive lymphomas, prior allogeneic HSCT, or any history of CNS lymphoma or CNS disorders. Following lymphodepleting chemotherapy, Yescarta was administered as a single intravenous infusion with a target dose of 2 &times; 10<sup>6</sup> anti-CD19 CAR T cells/kg (maximum permitted dose: 2 x 10<sup>8</sup> cells). The lymphodepleting regimen consisted of cyclophosphamide 500 mg/m<sup>2</sup> intravenously and fludarabine 30 mg/m<sup>2</sup> intravenously, both given on the fifth, fourth, and third day before Yescarta.</p><p>&nbsp;</p><p>Of 123 patients with FL who underwent leukapheresis, 120 received Yescarta. Of the remaining three patients (2%) who were not treated, one was ineligible due to thrombocytopenia, one went into remission prior to initiating lymphodepletion, and one died of cardiac arrest. There were no manufacturing failures. Of the 120 patients with FL infused with Yescarta, the 81 consecutive patients included in the primary efficacy analysis had at least 9 months of potential follow-up from date of first response.</p><p>&nbsp;</p><p>Among the 81 patients with FL included in the primary efficacy analysis, the median age was 62 years (range: 34 to 79 years), 46% were female, 93% were white, 4% were black, and 3% were Asian. The median number of prior systemic therapies was 3 (range: 2 to 9), with 32% having 2 prior lines, 22% having 3 prior lines, and 46% having &ge; 4 prior lines. Thirty-one percent had received a PI3K inhibitor, 72% had progression within 6 months of the most recent regimen, and 56% had progression within 24 months of initiating their first anti-CD20 combination therapy. Between leukapheresis and administration of Yescarta, one patient (1%) in the primary efficacy analysis received bridging therapy.</p><p>&nbsp;</p><p>Among the 81 patients included in the primary efficacy analysis, the median time from leukapheresis to product delivery was 17 days (range: 13 to 33 days) and leukapheresis to product infusion was 27 days (range: 19 to 250 days). The median dose of Yescarta was 2.0 &times; 10<sup>6</sup> CAR T cells/kg (range 1.3 to 2.1 &times; 10<sup>6</sup> CAR T cells/kg). &nbsp;All treated patients received Yescarta infusion on day 0 and were hospitalized until at least day 7.</p><p>&nbsp;</p><p>Efficacy was established on the basis of objective response rate and DOR as determined by an independent review committee (Table 12 and Table 13). The median time to response in the primary efficacy population was 1.0 month (range: 0.8 to 3.1 months). &nbsp;</p><p>&nbsp;</p><p><strong>Table 12. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Response Rate in Patients with Relapsed or Refractory FL in ZUMA-5</strong></p><table border="1" cellspacing="0" cellpadding="0" summary="Table 8. Response Rate in Patients with Relapsed or Refractory FL
                                                                                                                             Primary Efficacy Analysis (N=81). All Leukapheresed Patients (N=123)
Objective Response Rate Refer to footnote a.  Primary Efficacy Analysis (N=81). n=74 (91%), 95% CI: (83, 96). All Leukapheresed Patients (N=123). n=100 (89%), 95% CI: (83, 94).
Complete Remission. Refer to footnote b.  Primary Efficacy Analysis (N=81). n= 49 (60%), 95% CI: (49, 71). All Leukapheresed Patients (N=123). n=76 (62%), 95% CI: (53, 70).
Partial Remission. Primary Efficacy Analysis (N=81). n =25 (31%), 95% CI: (21, 42).  All Leukapheresed Patients (N=123). n=34 (28%), 95% CI: (20, 36).
                                                                                                                          Footnotes:                                                                                                                   CI, confidence interval.
a. Per the International Working Group Lugano Classification (Cheson 2014), as assessed by the independent review committee.
b. Complete remission required documentation of a negative bone marrow biopsy after treatment, in patients who did not have a negative bone marrow biopsy between their most recent disease progression prior to ZUMA-5 and initiation of lymphodepleting chemotherapy.
" style="width:98%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>Primary Efficacy Analysis</strong></p><p><strong>(N = 81)</strong></p></td><td style="vertical-align:bottom"><p><strong>All Leukapheresed Patients</strong></p><p><strong>(N = 123)</strong></p></td></tr><tr><td><p><strong>Objective Response Rate<sup>a</sup></strong>, n</p><p>(95% CI)</p></td><td><p>74 (91%)</p><p>(83, 96)</p></td><td><p>110 (89%)</p><p>(83, 94)</p></td></tr><tr><td><p>Complete Remission<sup>b</sup>, n</p><p>(95% CI)</p></td><td><p>49 (60%)</p><p>(49, 71)</p></td><td><p>76 (62%)</p><p>(53, 70)</p></td></tr><tr><td><p>Partial Remission, n</p><p>(95% CI)</p></td><td><p>25 (31%)</p><p>(21, 42)</p></td><td><p>34 (28%)</p><p>(20, 36)</p></td></tr></tbody></table><p>CI, confidence interval.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Per the International Working Group Lugano Classification (Cheson 2014), as assessed by the independent review committee.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete remission required documentation of a negative bone marrow biopsy after treatment, in patients who did not have a negative bone marrow biopsy between their most recent disease progression prior to ZUMA-5 and initiation of lymphodepleting chemotherapy.</p><p><strong>&nbsp;</strong></p><p><strong>Table 13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Duration of Response in Patients with Relapsed or Refractory FL in ZUMA-5</strong></p><table border="0" cellspacing="0" cellpadding="0" summary="Table 10. Duration of Response in Patients with Relapsed or Refractory FL From N of 81                                                                                             Number of Responders 74.                                                                                 Number of Responders. DOR (Months). Refer to footnote a.
DOR. Median in months: Refer to footnote b. NE, (95% CI) (20.8, NE)       DOR. Range. Refer to footnote c.  0.0, 25.0+
Rate of Continued Remission. Refer to footnote a, b,  and d.                             At 12 months (95% CI), % 76.2 (63.9, 84.7)                                                      At 18 months (95% CI), % 74.2 (61.5, 83.2)                                                                 Median Follow-up for DOR (Months). Refer to footnote a and b. 14.5    Footnotes:                                                                                                           CR, complete remission; DOR, duration of response; NE, not estimable; PR, partial remission. 
a. Among  all responders in the primary efficacy population.  DOR is measured from the date of first objective response to the date of progression or death from any cause.
b. Kaplan-Meier estimate.
c. A “+” sign indicates a censored value
d. Measured from the date of first objective response to the date of progression or death.
" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>From N of 81</strong></p></td></tr><tr><td><p><strong>Number of Responders</strong></p></td><td><p>74</p></td></tr><tr><td><p><strong>DOR (Months)</strong><sup>a<strong> </strong></sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Median<sup>b</sup></p></td><td><p>NE</p></td></tr><tr><td><p>(95% CI)</p></td><td><p>(20.8, NE)</p></td></tr><tr><td><p>Range<sup>c</sup></p></td><td><p>0.0, 25.0+</p></td></tr><tr><td><p><strong>Rate of Continued Remission</strong><sup>a, b, d</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>At 12 months (95% CI), %</p></td><td style="vertical-align:bottom"><p>76.2 (63.9, 84.7)</p></td></tr><tr><td><p>At 18 months (95% CI), %</p></td><td style="vertical-align:bottom"><p>74.2 (61.5, 83.2)</p></td></tr><tr><td><p><strong>Median Follow-up for DOR (Months)</strong><sup>a, b</sup></p></td><td><p>14.5</p></td></tr></tbody></table><p>CR, complete remission; DOR, duration of response; NE, not estimable; PR, partial remission.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Among all responders in the primary efficacy population.&nbsp; DOR is measured from the date of first objective response to the date of progression or death from any cause.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier estimate.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A &ldquo;+&rdquo; sign indicates a censored value.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Measured from the date of first objective response to the date of progression or death.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following infusion of Yescarta, anti-CD19 CAR T cells exhibited an initial rapid expansion followed by a decline to near baseline levels by 3 months. Peak levels of anti-CD19 CAR T cells occurred within the first 7 - 14 days after Yescarta infusion.</p><p>&nbsp;</p><p>Age (range: 21 to 80 years) and gender had no significant impact on AUC Day 0 - 28 and C<sub>max </sub>of Yescarta.</p><p>&nbsp;</p><p><em>Large B-cell Lymphoma</em></p><p>Among patients with LBCL in the ZUMA-1 study (n=96 evaluable), the number of anti-CD19 CAR T cells in blood was positively associated with objective response (CR or PR). The median anti-CD19 CAR T cell C<sub>max</sub> levels in responders (n=73) were 205% higher compared to the corresponding level in nonresponders (n=23) (43.6 cells/&mu;L vs 21.2 cells/&mu;L). Median AUC Day 0 - 28 in responding patients (n=73) was 251% of the corresponding level in nonresponders (n=23) (557.1 days &times; cells/&mu;L vs. 222.0 days &times; cells/&mu;L).</p><p>&nbsp;</p><p>Among patients with LBCL in the ZUMA-7 study (n=162 evaluable), the number of anti-CD19 CAR T cells in blood was positively associated with objective response [complete remission (CR) or partial remission (PR)]. The median anti-CD19 CAR T cell C<sub>max</sub> levels in responders (n=142) were 275% higher compared to the corresponding level in nonresponders (n=20) (28.9 cells/&mu;L vs 10.5 cells/&mu;L). Median AUC Day 0 - 28 in responding patients (n=142) was 418% of the corresponding level in nonresponders (n=20) (292.9 days &times; cells/&mu;L vs. 70.1 days &times; cells/&mu;L). No association between peak anti-CD19 CAR T-cell levels and OS was observed among 163 subjects with an evaluable pharmacokinetic sample when anti-CD19 CAR T-cell peaks were categorized as &gt; median relative to &le; median.</p><p>&nbsp;</p><p><em>Follicular Lymphoma</em></p><p>Among patients with FL in the ZUMA-5 study (n=81 evaluable), the median anti-CD19 CAR T cell C<sub>max</sub> levels in responders (n=74) were 40.1 cells/&mu;L and 46.0 cells/&mu;L in nonresponders (n=7). The median AUC Day 0 - 28 in responding FL patients (n=74) were 465.8 days &times; cells/&mu;L and 404.5 days &times; cells/&mu;L in nonresponders (n=7).&nbsp;</p><p>&nbsp;</p><p>Some patients required tocilizumab and corticosteroids for management of CRS and neurologic toxicities. Patients treated with tocilizumab (n=44) had 262% and 232% higher anti-CD19 CAR T cells as measured by AUC Day 0 - 28 and C<sub>max</sub> respectively, as compared to patients who did not receive tocilizumab (n=57). Similarly, patients that received corticosteroids (n=26) had 217% and 155% higher AUC Day 0 - 28 and C<sub>max</sub> compared to patients who did not receive corticosteroids (n=75).</p><p>&nbsp;</p><p>Hepatic and renal impairment studies of Yescarta were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No carcinogenicity or genotoxicity studies have been conducted with Yescarta. No studies have been conducted to evaluate the effects of Yescarta on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cryostor CS10</p><p>Sodium chloride</p><p>Human albumin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Yescarta is stable for 1 year when stored frozen in the vapour phase of liquid nitrogen (≤ -150 ˚C).

The stability of Yescarta upon completion of thawing is up to 3 hours at room temperature (20 ˚C to 25 °C). However, Yescarta infusion should begin within 30 minutes of thaw completion and the total Yescarta infusion time should not exceed 30 minutes. Thawed product should not be refrozen.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Yescarta bags must be stored in the vapour phase of liquid nitrogen (&le; -150 ˚C) and Yescarta must remain frozen until the patient is ready for treatment to ensure viable live autologous cells are administered to the patient.</p><p>&nbsp;</p><p>For storage conditions after thawing of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ethylene-vinyl acetate cryostorage bag with sealed addition tube and two available spike ports, containing approximately 68 mL of cell suspension.</p><p>&nbsp;</p><p>One cryostorage bag is individually packed in a shipping cassette.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irradiation could lead to inactivation of the product.</p><p>&nbsp;</p><p><u>Precautions to be taken for transport and disposal of the medicinal product</u></p><p><u>&nbsp;</u></p><p>Yescarta should be transported within the facility in closed, break-proof, leak-proof containers.</p><p>Yescarta contains genetically-modified human blood cells. Local guidelines on handling of waste of human-derived material should be followed for unused medicinal products or waste material. All material that has been in contact with Yescarta (solid and liquid waste) should be handled and disposed of in accordance with local guidelines on handling of waste of human-derived material.</p><p>&nbsp;</p><p>Accidental exposure to Yescarta must be avoided. Local guidelines on handling of waste of human derived-materials should be followed in case of accidental exposure, which may include washing of the contaminated skin, and removal of contaminated clothes. Work surfaces and materials which have potentially been in contact with Yescarta must be decontaminated with appropriate disinfectant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gilead Sciences Ireland UC, 
Carrigtohill, 
County Cork, 
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2023
SFDA-APR24-US-FDA MAR24 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>